Wallace V. Crandall, M.D., M.M.M.

PRESENT TITLES & AFFILIATION

Associate VP-Medical, Immunology

GI Therapeutic Area Head

Eli Lilly and Company

-Responsible for the global phase 3 adult and pediatric development programs of the GI therapeutic area.

CITIZENSHIP/VISA STATUS

United States Citizen

OFFICE ADDRESS

Lilly Corporate Center

Building 88

Indianapolis Indiana, 46285

EDUCATION

UNDERGRADUATE TRAINING

1990	Utah State University	B.S.

Logan, Utah

GRADUATE TRAINING

1994 University of Utah School of Medicine M.D.

Salt Lake City, Utah

2016 Masters of Medical Management M.M.M.

Carnegie Mellon University

POSTGRADUATE TRAINING

1004 1007	C, T ' C1'11 ' II ', 1	D '1 ' D 1' '
100/1100/	St I ollie ("hildren'e Hoenital	Pacidant in Padiatrice
1994-1997	St. Louis Children's Hospital	Resident in Pediatrics

Washington University Medical Center

St. Louis, Missouri

1997-2000 St. Louis Children's Hospital Fellow, Pediatric

> Washington University Medical Center Gastroenterology &

> St. Louis, Missouri

Nutrition

ADDITIONAL TRAINING

2004-2006 Medical Leadership Program

Nationwide Children's Hospital

Columbus, Ohio

2009 "Mini" Advanced Training Program in Quality Improvement

Institute for Health Care Delivery Research

Intermountain Health Care Salt Lake City, Utah

2010-2011 Advanced Improvement Methods

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio

2017 Drucker Un-Workshop- Gearing for Innovation

Drucker Institute Claremont, California

UNIVERSITY, HOSPITAL AND CORPORATE APPOINTMENTS AND COMMITTEES

Washington University/St. Louis Children's Hospital

2014

1999 House staff Advisory Committee, Washington University School

of Medicine

The Ohio State University/Nationwide Children's Hospital

2000	Clinical Assistant Professor of Pediatrics, The Ohio State
	University
2003	Assistant Professor of Clinical Pediatrics, The Ohio State
	University
2005	Office of Clinical Sciences, Intramural Funding Reviewer/
	Research Release Time Committee, Nationwide Children's
	Hospital
2006	Associate Professor of Clinical Pediatrics, The Ohio State
	University
2008	Transition of Care Committee, Nationwide Children's Hospital
2009	Search Committee, OSU IBD Director
2009 - 2018	Safety Committee, Nationwide Children's Hospital
2010	EDW Steering Committee, Nationwide Children's Hospital
2011 - 2018	Professor of Clinical Pediatrics, The Ohio State University
2012 - 2018	Quality Committee, Nationwide Children's Hospital
2012 - 2014	Associate Medical Director for Quality, Nationwide Children's
	Hospital

Search Committee, Division and Section Chief of Psychology

2014 2010	
2014 - 2018	Medical Director, Quality Improvement Services, Nationwide
2014 2010	Children's Hospital
2014 - 2018 2015	Physician Review Committee
	Search Committee, Division Chief of Rheumatology
2015 - 2018	QI/IS Coordinating Committee
2015 - 2018	Grievance Committee
2015 - 2018	GME Committee
2016 - 2018	Co-Director, Clinical Fellowship in Quality and Safety Leadership
2016 - 2018	Promotion and Tenure Committee
2016 - 2018	International Clinical Triage and Advisory Committee
2016 - 2018	Enterprise Data Science Steering Committee
2016- 2018	Search Committee, Division Chief of Ambulatory Pediatrics
Eli Lilly and Company	
2019- 2021	Medical Fellow/Senior Medical Lead, Pediatric Immunology, Lilly
2019- 2022	Clinical Research Physician, Immunology, Lilly
2019-Present	Pediatric Steering Committee/Pediatric Center of Excellence Lead
	Team, Lilly
2019-2024	I-ACT-Lilly Core Team
2019-2024	Member, Connect 4 Children Work Package 4
2019-2024	Member, Connect 4 Children TrialComm
2020- 2024	Member, Connect 4 Children Quality Board
2020	Pediatric Covid Taskforce (Lilly)
2020-2021	Organizing Committee, c4c Multi-Stakeholder Meeting on
	Pediatric IBD
2022-2022	Lead, Team Lilly Champion, Immunology
2021-2022	Organizing Committee and Sponsor, I-ACT Advancing Pathways
	for the Development of Innovative Therapies for Children With
	Inflammatory Bowel Disease (IBD) Webinar Series
2021-2022	Senior Medical Fellow, Senior Medical Lead, Pediatric
	Immunology, Lilly
2022- 2022	Senior Medical Fellow; Adult Ulcerative Colitis and Pediatric
	Ulcerative Colitis and Crohn's Disease Programs, Lilly
2022-Present	Associate VP-Medical, Immunology- GI Therapeutic Area Head,
	Lilly
2022-Present	Pediatric Center of Excellence (Peds COE) Growth and
	Development Working Group
2023-Present	Titles and Promotions Committee, Lilly
2023-Present	Global Product Labeling Committee, Lilly (GPLC), Delegate
2023-Present	Probability Assessment Group, Observer (PAG)
2023-Present	Lilly Bioethics Committee
2024-Present	FDA Gastrointestinal Drugs Advisory Committee (GIDAC).
	- · · · · · · · · · · · · · · · · · · ·

MEDICAL LICENSURE AND BOARD CERTIFICATION

1994	National Board of Medical Examiners
1995	Missouri Medical License – MD 106357

1997- 2004 American Board of Pediatrics

2000 Ohio Medical License- 35-07-8095-C (Active) 2001- Present American Board of Pediatrics, Sub-board Pediatric

Gastroenterology

HONORS & AWARDS

1987	Golden Key National Honor Society
1990	Phi Kappa Phi National Honor Society
1990	Outstanding Senior in Health Education
1990	Departmental Outstanding Scholar
1990	Departmental Valedictorian
1990	Kiwanis Club Outstanding Student Award
1990	Graduated Summa Cum Laude
1993	Alpha Omega Alpha
1993	Pediatrics Honors Program
1993	Olin Scholarship in Pediatrics
2000	Mead-Johnson "Best Research Paper" Award
2000	NASPGN/World Congress Meeting-Young Investigator Award
2007	NCH Quality Expo Awards, "Best CQI Tools and Fan Favorite"
2009	NCH Quality Expo Awards, "Most Effective Use of Data"
2015	APGNN Mentor Award
2019	Nominee Pediatric Excellence Award (In-eligible to receive an
	aware given full time pediatric role at the time.)
2019	Lilly Innovation Award Recognition
2020	Lilly Innovation Award Recognition
2020	Top 100 Lilly Innovator Award
2022	Top 100 Lilly Innovator Award
2023	Lilly Innovation Award Recognition

OTHER PROFESSIONAL/PUBLIC SERVICE

GLUTEN FREE GANG

2000-2009 Medical Advisor to the "Gluten Free Gang" (Regional celiac

disease support group)

CROHN'S AND COLITIS FOUNDATION

2001-2004 Chairman, Chapter Medical Advisory Committee, Central Ohio

Chapter

2001-2004 Crohn's and Colitis Foundation of America-Chairman, Tribute

Dinner Committee,

2003-2004 National Working Group "Prevention of Post-operative Recurrence

of Crohn's Disease."

2005 Pediatric Clinical Trials Taskforce

2006-2009	National Pediatric Education Committee
2008-2011	Board Member, CCFA Central Ohio Chapter
2010-2012	Pediatric Affairs Committee (NASPGHAN liaison)
2010-2012	National Scientific Advisory Board (NASPGHAN liaison)
2012	"Advances in IBD" Abstract Review Committee
2013 - 2016	PROKIIDS Steering Committee

NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY

NORTH AMERICAN SOCI	ETY FOR PEDIATRIC GASTROENTEROLOGY,
	HEPATOLOGY, AND NUTRITION
2001-2004	Clinical practice committee
2003-2004	Chair, Workforce Survey
2003	IBD Binder Committee
2005-2010	Inflammatory Bowel Disease Committee, two terms
2007-2010	Co-Chairperson, IBD Quality Improvement Task Force
2009	Task Force on Training in Inflammatory Bowels Diseases
2009-2010	Vice Chair, IBD Committee
2010-2012	Chair, IBD Committee
2012	Chair and Conference Organizer, "Discovering the Future of
	Pediatric Inflammatory Bowel Disease Care", Salt Lake City UT,.
2012	Co-Organizer and Moderator, FDA Sponsored Gastroenterology
	Regulatory Endpoints and the Advancement of Therapeutics

(GREAT); Public Workshop. Baltimore MD

(GREATT), I done workshop.

2013 Nominating Committee

PEDIATRIC IBD NETWORK FOR RESEARCH AND IMPROVEMENT

2004-2009 Advisor

THE CENTER FOR PEDIATRIC AND ADOLESCENT INFLAMMATORY BOWEL

DISEASE, NATIONWIDE CHILDRENS HOSPITAL

2005 - 2018 Director

CDHNF SCIENTIFIC ADVISORY BOARD, CAMPAIGN ON PEDIATRIC IBD

2005 Co-Chairperson, Adherence Task Group for the CDHNF College

Bound IBD Management Guide

2005 Chair, Adherence Webcast

IMPROVE CARE NOW IMPROVEMENT COLLABORATIVE

2008-2010 Chair, Measurement Committee

2009-2010 Steering Committee

2010 Chair, NASPGHAN/ImproveCareNow IBD QI Activity

2010 – 2018 Director of Quality Improvement,

2010-2014 Executive Committee

2010-2013 Integration Steering Committee (Responsible for coordinating the

work of ICN and the grant teams from "C3N" and "Enhanced

Registries")

2014 – 2018 Physician Leadership Group

2014 – 2017 Strategy Council

2017 – 2018 Co-Chair, Data and Measurement Leadership Committee

PEDIATRIC GASTROENTEROLOGY FELLOWSHIP, NATIONWIDE CHILDRENS

HOSPITAL

2008-2012 Associate Director

THE CLINICAL AND TRANSLATIONAL RESEARCH INTRAMURAL FUNDING

PROGRAM, NATIONWIDE CHILDRENS HOSPITAL

2008-2010 Review Committee

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

2009 - 2010 Abstract review committee (Clinical Pediatric Gastroenterology,

Other), DDW

2011 Chair, abstract review committee (Clinical Pediatric

Gastroenterology, Other), DDW

NIH CHALLENGE GRANTS

2009 Stage 1 Reviewer

CCFA RISK STRATIFICATION STUDY

2009-2014 Publication Committee

INSTITUTE FOR HEALTHCARE IMPROVEMENT

2016 Abstract review committee, IHI Scientific Symposium

JOURNAL REVIEWER

Journal of Pediatric Gastroenterology and Nutrition

Inflammatory Bowel Diseases

Journal of Pediatrics Academic Pediatrics

JAMA

Pediatric Quality and Safety

JOURNAL EDITOR

2010 - 2012 Section Editor (Pediatrics), Inflammatory Bowel Diseases

2016 - 2018 Editorial Board, Pediatric Quality and Safety

FACULTY OF 1000

2012-2014 Founding Member- Pediatric Gastroenterology and Hepatology

PATIENT CENTERED OUTCOMES RESEARCH NETWORK (PCORNet) CLINICAL

TRIALS TASK FORCE

2014 - 2016

OHIO GOVERNOR'S OFFICE OF HEALTH TRANSFORMATION

2015 Clinical Advisory Group

AAP PEDIALINK

2015 - 2018 QI Oversight Committee

CHILDREN'S HOSPITAL ASSOCIATION

2017-2018 Steering Committee; Quality and Safety Leader's Forum

SCHOLARSHIP OVERSIGHT COMMITTEE

2005 - 2008	Jaya Punati, M.D.
2006 - 2009 (Chair)	Kyle Kusek M.D.
2007 - 2010 (Chair)	Brendan Boyle, M.D.
2007 - 2010	Molly Dienhart, M.D.
2008 - 2011	Maria Perez, M.D.
2009 - 2012	Ala Shaikhkhalil, M.D.
2009 - 2012 (Chair)	Jen Dotson, M.D.
2010 - 2013	Soma Kumar, M.D.
2015 - 2018	Amina Habib, M.D., MHA
2015 - 2018	Briana Bertoni, M.D.
2016 - 2018	Amy Peasley, M.D.
2016 - 2017	Kate Ellery, MD
2017 - 2018	Rose Lee, MD

PUBLICATIONS

EDITED BOOKS

1. **Crandall WV**, Hommel KA, Perez ME. Living Well with Inflammatory Bowel Disease; A Self-Management Handbook for Patients and Families with IBD. 2011 (PDF made available free of charge through the ImproveCareNow website).

CHAPTERS IN EDITED BOOKS

- 1. **Crandall WV**. Gastroenterology. In Holland-Hall CM, Brown RT (Eds). Adolescent Medicine Secrets. Philadelphia, Hanley &Belfus, 2002.
- Mackner LM, Crandall WV. Gastrointestinal Disorders. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 253-255, New York, Klumer Academic/Plenum, 2003
- 3. Mackner LM, **Crandall WV**. Celiac Disease. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 85-86, New York, Klumer Academic/Plenum, 2003

- 4. Mackner LM, Crandall WV. Diarrhea. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 181-182, New York, Klumer Academic/Plenum, 2003
- 5. Mackner LM, **Crandall WV**. Food Allergy. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 243-244, New York, Klumer Academic/Plenum, 2003
- 6. Mackner LM, Crandall WV. Functional Dyspepsia. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 250-251, New York, Klumer Academic/Plenum, 2003
- 7. Mackner LM, **Crandall WV**. Gastroesophageal Reflux Disease. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 252-253, New York, Klumer Academic/Plenum, 2003
- 8. Mackner LM, **Crandall WV**. Hirschprung's Disease. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 289-290, New York, Klumer Academic/Plenum, 2003
- 9. Mackner LM, Crandall WV. Irritable Bowel Syndrome. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 326-327, New York, Klumer Academic/Plenum, 2003
- 10. Mackner LM, **Crandall WV**. Inflammatory Bowel Disease. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 211-212, New York, Klumer Academic/Plenum, 2003
- 11. Mackner LM, **Crandall WV**. Peptic Ulcer Disease. In Ollendick T, Schroeder C (Eds). Encyclopedia of Pediatric and Child Psychology. 467-468, New York, Klumer Academic/Plenum, 2003
- 12. Mackner LM, **Crandall WV**. Psychological Aspects of IBD in Children and Adolescents. In Mamula et al. (Eds.) Pediatric Inflammatory Bowel Disease. 548-552, Springer Science + Business Media, LLC, 2007
- 13. Nwomeh B, **Crandall WV**. Radiologic Evaluation of Pediatric Inflammatory Bowel Disease. In Mamula et al. (Eds.) Pediatric Inflammatory Bowel Disease. Springer Science + Business Media, LLC, 2008
- 14. Russo JM, **Crandall WV**. Transition of Care. In Scherl and Dubinsky (Eds.) The Changing World of Inflammatory Bowel Disease. NJ, SLACK Incorporated, 2009.
- 15. **Crandall WV**. Managing Specific Problems. In Oliva-Hemker M, Ziring D, Bousvaros A. (Eds.), Your Child with Inflammatory Bowel Disease. 139-157, Maryland, John Hopkins Press, 2010.

- 16. Mackner LM, **Crandall, WV.** (2013). Psychological Aspects of IBD in Children and Adolescents. In *Pediatric Inflammatory Bowel Disease* (pp. 483-490). Springer New York.
- 17. Colletti, R. B., Kappelman, M. D., **Crandall, WV**, & Margolis, P. A. (2013). Quality Improvement in Inflammatory Bowel Disease. In *Pediatric Inflammatory Bowel Disease* (pp. 547-554). Springer New York.
- 18. Mackner L, **Crandall WV.** Are there emotional issues that are commonly seen in pediatric IBD that I should look for in my patients and their families? In Rosh and Bousvaros (Eds.) Curbside Consultation in Pediatric GI: 49 Clinical Questions, First Edition. Slack
- 19. Lee AY, Taghon T, McClead R, **Crandall WV**, Davis T, Brilli RJ. (2015). Safety and Quality in the Heart Center. In *Moss and Adam's Heart Disease* 9th Edition (pp. 1781-1793). Wolters Kluwer.
- 20. Forrest, C. B., Becker, B. D., Teneralli, R. E., Moon, J., Tucker, C. A., Crandall, W., & Bevans, K. B. (2016, October). Cross-sectional and longitudinal construct validity of PROMIS (R) pediatric short form item banks in children with inflammatory bowel disease. In *QUALITY OF LIFE RESEARCH* (Vol. 25, pp. 57-58). VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS: SPRINGER.
- 21. Reed-Knight, B., Mackner, L. M., & Crandall, W. V. (2017). Psychological Aspects of Inflammatory Bowel Disease in Children and Adolescents. In *Pediatric Inflammatory Bowel Disease* (pp. 615-623). Springer International Publishing.
- 22. Adler, J., Colletti, R. B., Crandall, W. V., & Margolis, P. A. (2017). Quality Improvement in Inflammatory Bowel Disease. In *Pediatric Inflammatory Bowel Disease* (pp. 685-695). Springer International Publishing.

BULLETINS AND TECHNICAL REPORTS

1. Training Guideline in Pediatric IBD. JPGN

PEER-REVIEWED JOURNAL ARTICLES

1. **Crandall WV**, Norlin C, Bulock EA, Shearrow ME, Tani LY, Orsmond GS, Shaddy RE. Etiology and Outcome of Outpatient Fevers in Pediatric Heart Transplant Patients. Clin Pediatr 1996 Sep;35(9):437-42.

- 2. **Crandall WV**, Langer JC. Primary Omental Torsion Presenting as Hip Pain and Limp. J Pediatr Gastroenterol Nutr 1999 Jan;28(1):95-96.
- 3. **Crandall WV**, Lowe ME. Colipase Residues Glu⁶⁴ and Arg⁶⁵ are Essential for Normal Lipase Mediated Fat Digestion in the Presence of Bile Salt Micelles. J Biol Chem 2001 Apr 20;276(16):12505-12.
- 4. **Crandall WV**, Mackner LM. Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome, and a Predictive Model. Alim Phar Ther. 2003 Jan 17:75-84.
- 5. Moulton DE, **Crandall WV**, Lakhani R, Lowe ME. Expression of a Novel Cadherin in the Mouse and Human Intestine. Pediatr Res. 2004 Jun;55(6):927-34.
- 6. Mackner LM, Sisson DP, **Crandall WV**. Review: Psychosocial Issues in Pediatric Inflammatory Bowel Disease. J Pediatr Psychology. 2004 Jun;29(4):243-57
- 7. Stark LJ, Hommel KA, Mackner LM, Janicke DM, Davis AM, Pferrerkorn M, Crandall WV, Heubi J. Randomized Trial Comparing Two Methods of Increasing Dietary Calcium Intake in Children with Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr. 2005 April;40(4):501-7.
- 8. **Crandall WV**, Barnard, J, Cohen M, Coletti R, Ferry G, Harnsberger J, Hart M, Hayes J, Rosenthal P, Sherman P, Smith L. NASPGHAN Workforce Survey, 2004. J Pediatr Gastroenterol Nutr. 2005 April;40(4);397-405.
- 9. Mackner LM, **Crandall WV**. Long-term Psychosocial Outcomes Reported by Children and Adolescents with Inflammatory Bowel Disease Am J Gastroenterol 2005 June;100(6):1386-92.
- 10. Markowitz J, Markowitz J, Bousvaros A, **Crandall WV**, Faubion, William, Kirschner, Barbara S, Perrault, Jean, Rosh, Joel, Winter, Harland. Workshop Report: Prevention of Post-Operative Recurrence in Crohn's Disease. J Pediatr Gastroenterol Nutr. 2005 August;41(2):145-51.
- 11. Mackner LM, **Crandall WV**. Oral Medication Adherence in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2005 Nov;11(11):1006-1012.
- 12. Mackner LM, **Crandall WV**, Szigethy E M. Psychosocial Functioning in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2006 Mar;12(3):239-244.
- 13. Mackner LM, **Crandall WV**. Brief Report: Psychosocial Adjustment in Adolescents with Inflammatory Bowel Disease. J Pediatr Psychology 2006 Apr;31(3):281-285.

- 14. **Crandall WV**, Halterman TE, Mackner LM. Anxiety and Pain Symptoms in Children with Inflammatory Bowel Disease and Functional Gastrointestinal Disorders Undergoing Colonoscopy. J Pediatr Gastroenterol Nutr. 2007 Jan;44(1):63-67.
- 15. Hyams J, Crandall WV, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Chen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn's Disease in Children. Gastroenterology. 2007 Mar:132(3):863-73.
- 16. Mackner LM, **Crandall WV**. Psychological Factors Affecting Pediatric Inflammatory Bowel Disease. Curr Opin Pediatr. 2007 Oct;19(5):548-52.
- 17. Kugathasan S, Nebel J, Skelton JA, Markowitz J, Keljo D, Rosh J, LeLeiko N, Mack D, Griffiths A, Bousvaros A, Evans J, Mezoff A, Moyer S, Oliva-Hemker M, Otley A, Pfefferkorn M, **Crandall WV**, Wyllie R, Hyams J. Body Mass Index in Children with Newly Diagnosed Inflammatory Bowel Disease; Observations from Two Multicenter North American Inception Cohorts. J Pediatr. 2007 Nov;151(5):523-7.
- 18. Saeed S, **Crandall WV**. Managing Complicated Crohn's Disease in Children and Adolescents: Focus on TNF Antagonists. Pediatric Drugs. 2008 Jan;10(1):31-8.
- 19. Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, **Crandall WV**. Effect of Early Immunomodulator Use in Moderate to Severe Pediatric Crohn's Disease. Pediatric IBD Collaborative Research Group. Inflamm Bowel Dis. 2008 Jul;14(7):949-54.
- 20. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall WV, Langton C, Landers C, Taylor KD, Targan SR, Rotter JI, Markowitz J, Hyams J. Increased Immune reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Western Regional Pediatric IBD Research Alliance; Pediatric IBD Collaborative Research Group; Wisconsin Pediatric IBD Alliance. Clin Gastroenterol Hepatol. 2008 Oct;6(10):1105-11.
- 21. Hommel KA, Mackner LM, Denson LA, **Crandall WV**. Treatment Regimen Adherence in Pediatric Gastroenterology. J Pediatr Gastroenterol Nutr. 2008 Nov;47(5):526-43.
- 22. Hommel KA, Denson LA, **Crandall WV**, Mackner LM. Behavioral Functioning and Treatment Adherence in Pediatric Inflammatory Bowel Disease: Review and Recommendations for Practice. Gastroenterol Hepatol (N Y). 2008 Nov 1;4(11):785.
- 23. Thayu M, Leonard MB, Hyams JS, **Crandall WV**, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN. Improvement in Biomarkers of Bone Formation During Infliximab Therapy in

- Pediatric Crohn's Disease: Results of the REACH Study. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1378-84.
- 24. Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall WV, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth Abnormalities Persist in Newly Diagnosed Children with Crohn Disease Despite Current Treatment Paradigms. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):168-74.
- 25. Keljo DJ, Markowitz J, Langton C, Lerer T, Bousvaros A, Carvalho R, Crandall WV, Evans J, Griffiths A, Kay M, Kugathasan S, Leleiko N, Mack D, Mamula P, Moyer MS, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Hyams JS. Course and Treatment of Perianal Disease in Children Newly Diagnosed with Crohn's Disease. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Inflamm Bowel Dis. 2009 Mar;15(3): 383-7.
- 26. Markowitz J, Kugathasan S, Dubinsky M, Mei L, **Crandall WV**, Leleiko N, Oliva-Hemker M, Rosh J, Evans J, Mack D, Otley A, Pfefferkorn M, Bahar R, Vasiliauskas E, Wahbeh G, Silber G, Quiros JA, Wrobel I, Nebel J, Landers C, Picornell Y, Targan S, Lerer T, Hyams J. Age of Diagnosis Influences Serologic Responses in Children with Crohn's Disease: A Possible clue to Etiology? Inflamm Bowel Dis. 2009 May; 15 (5): 714-9.
- 27. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, **Crandall WV**, Oliva-Hemker M, Keljo D, Leleiko N, Markowitz J. Long-Term Outcome of Maintenance Infliximab Therapy in Children with Crohn's Disease. The Pediatric Inflammatory Bowel Disease Collaborative Research Group. Inflamm Bowel Dis. 2009 Jun; 15 (6): 816-22.
- 28. **Crandall W**, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Infliximab Therapy in Children with Concurrent Perianal Crohn's Disease: Observations from REACH. J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90.
- 29. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, Pfefferkorn M, Rosh J, Kay M, Crandall W, Keljo D, Otley AR, Kugathasan S, Carvalho R, Oliva-Hemker M, Langton C, Mamula P, Bousvaros A, Leleiko N, Griffiths AM; Pediatric IBD Collaborative Research Group. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis. 2009 Aug;15(8):1218-23.
- 30. Colletti RB, Baldassano RN, Milov DE, Margolis PA, Bousvaros A, **Crandall WV**, Crissinger KD, D'Amico MA, Day AS, Denson LA, Dubinsky M, Ebach DR, Hoffenberg EJ, Kader HA, Keljo DJ, Leibowitz IH, Mamula P, Pfefferkorn MD, Qureshi MA; for PIBDNet, the Pediatric IBD Network for Research and Improvement. Variation in Care in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):297-303.

- 31. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, **Crandall W**, Carvalho RS, Mack DR, Hyams JS. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease. Am J Gastroenterol. 2009 Dec;104(12):3042-9.
- 32. Turner D, Kolho KL, Mack DR, Raivio T, Leleiko N, **Crandall W**, Markowitz J, Silverberg MS, Jänne OA, Stempak J, Hyams J, Griffiths AM. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis. 2010 Mar;16(3):469-73.
- 33. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Grossman A, Tomer G, Kay M, **Crandall W**, Oliva-Hemker M, Keljo D, Leleiko N, Markowitz J. Outcome Following Infliximab Therapy in Children with Ulcerative Colitis. Am J Gastroenterol. 2010 Jun;105(6):1430-6.
- 34. Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, **Crandall W**, Silverberg M, Markowitz J, Otley AR, Keljo D, Mamula P, Kugathasan S, Hyams J, Griffiths AM. Severe Pediatric Ulcerative Colitis: A Prospective Multicenter Study of Outcomes and Predictors of Response. Gastroenterology. 2010 Jun;138(7):2282-91.
- 35. Boyle B, Mackner L, Ross C, Moses J, Kumar S, **Crandall W**.A Single-Center Experience with Methotrexate after Thiopurine Therapy in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 2010 Dec;51(6):714-7.
- 36. Dotson JL, Hyams JS, Markowitz J, Leleiko NS, Mack DR, Evans JS, Pfefferkorn MD, Griffiths AM, Otley AR, Bousvaros A, Kugathasan S, Rosh JR, Keljo D, Carvalho RS, Tomer G, Mamula P, Kay MH, Kerzner B, Oliva-Hemker M, Langton CR, Crandall W. Extra-Intestinal Manifestations of Pediatric Inflammatory Bowel Disease and Their Relation to Disease Type and Severity. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):140-5.
- 37. Turner D, Leach S, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters T, **Crandall W**, Markowitz J, Otley A, Griffths A, Day A. Fecal calprotectin, lactoferrin, M2-pyruvate kinase, and S100A12 in severe ulcerative colitis: a prospective multicenter comparison of predicting outcomes and monitoring response. Gut. 2010 Sep;59(9):1207-12.
- 38. Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, **Crandall W**, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM, Silverberg MS. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One. 2010 Sep 30;5(9).
- 39. Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, **Crandall W**, Mack DR, Evans JS, Pfefferkorn MD, Griffiths AM, Otley AR, Bousvaros A, Kugathasan S, Rosh

- JR, Keljo DJ, Carvalho RS, Tomer G, Mamula P, Kay MH, Kerzner B, Oliva-Hemker M, Kappelman MD, Saeed SA, Hyams JS, Leleiko NS. Factors that Determine Risk for Surgery in Pediatric Patients with Crohn's Disease. Clin Gastroenterol Hepatol. 2010 Sep;8(9):789-94.
- 40. Kappelman MD, **Crandall WV**, Colletti RB, Goudie A, Leibowitz IH, Duffy L, Milov DE, Kim SC, Schoen BT, Patel AS, Grunow J, Larry E, Fairbrother G, Margolis P. Short Pediatric Crohn's Disease Activity Index for Quality Improvement and Observational Research. Inflamm Bowel Dis. 2011 Jan;17(1):112-7.
- 41. Dotson J, **Crandall W**, Mousa H, Honegger JR, Denson L, Samson C, Cunningham D, Balint J, Dienhart M, Jaggi P, Carvalho, R. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha therapy: A case series. Inflamm Bowel Dis. 2011 Jan;17(1):56-61.
- 42. **Crandall W**, Kappelman MD, Colletti RB, Leibowitz I, Grunow JE, Ali S, Baron HI, Berman JH, Boyle B, Cohen S, Del Rosario F, Denson LA, Duffy L, Integlia MJ, Kim SC, Milov D, Patel AS, Schoen BT, Walkiewicz D, Margolis P. ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011 Jan;17(1):450-7.
- 43. Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, **Crandall W**, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. A Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis. 2011 Jan;17(1):30-8.
- 44. Mackner LM, Clough-Paabo E, Pajer K, **Crandall W**. Psychoneuroimmunologic factors in inflammatory bowel disease. Inflamm Bowel Dis. 2011 Mar;17(3):849-57.
- 45. Hyams J, Walters TD, **Crandall W**, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011 Mar;27(3):651-62.
- 46. Hyams JS, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J, Otley A, Evans J, Stephens M, Kay M, Keljo D, Pfefferkorn M, Saeed S, **Crandall W**, Michail S, Kappelman MD, Grossman A, Samson C, Sudel B, Oliva-Hemker M, Leleiko N, Markowitz J. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011 May;106(5):981-7.
- 47. Dotson J, **Crandall W**, Bout-Tabaku S. Exploring the differential diagnosis of joint complaints in pediatric patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2011 Jun;13(3):271-8.

- 48. Sylvester FA, Turner D, Draghi A 2nd, Uuosoe K, McLernon R, Koproske K, Mack DR, Crandall WV, Hyams JS, Leleiko NS, Griffiths AM. Fecal Osteoprotegerin May Guide the Introduction of Second Line Therapy in Hospitalized Children with Ulcerative Colitis. Inflamm Bowel Dis. 2011 Aug;17(8):1726-30.
- 49. Long M, Crandall W, Leibowitz I, Duffy L, del Rosario F, Kim S, Integlia M, Berman J, Grunow J, Colletti R, Schoen B, Patel P, Baron H, Israel E, Russell G, Ali S, Herfarth H, Martin C, Kappelman M. The Prevalence and Epidemiology of Overweight and Obesity in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2011 Oct;17(10):2162-8.
- 50. Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, Kasirer Y, Muise A, Seow CH, Silverberg MS, **Crandall W**, Griffiths AM. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis. 2011 Oct;5(5):423-9.
- 51. **Crandall WV**, Boyle BM, Colletti RB, Margolis PA, Kappelman MD. Development of Process and Outcome Measures for Improvement-Lessons Learned in a Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2011 Oct;17(10):2184-91.
- 52. Mackner LM, Bickmeier RM, **Crandall WV**. Academic Achievement, Attendance, and School-Related Quality of Life in Pediatric Inflammatory Bowel Disease. J Dev Behav Pediatr. 2012 Feb;33(2):106-11.
- 53. Mackner, L. M., Vannatta, K., & **Crandall, WV.** (2012). Gender differences in the social functioning of adolescents with inflammatory bowel disease. *Journal of clinical psychology in medical settings*, 19(3), 270-276.
- 54. **Crandall WV**, Margolis PA, Kappelman MD, King EC, Pratt JM, Boyle BM, Duffy LF, Grunow JE, Kim SC, Leibowitz I, Schoen BT, Colletti RB, for the ImproveCareNow Collaborative. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics. 2012 Apr;129(4):e1030-e1041.
- 55. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC, Veereman-Wauters G, **Crandall W**, Baldassano R, Griffiths A. Induction and Maintenance Therapy with Infliximab for Children with Moderate-to-Severe Ulcerative Colitis Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-399.e1
- 56. Lee GJ, Kappelman MD, Boyle B, Colletti RB, King E, Pratt JM, Crandall WV. Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012 Dec;55(6):701-6.
- 57. Eytan Wine E, Mack D, Hyams J, Otley A, Markowitz J, **Crandall W**, Leleiko N, Muise A, Griffiths A, Turner D. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013 Jan 19. doi:pii: S1873-9946(12)00508-9

- 58. **Crandall WV**, Davis JT, McClead R, Brilli RJ. Is preventable harm the right patient safety metric? Pediatr Clin North Am. 2012 Dec;59(6):1279-92.
- 59. Dotson JL, Nwomeh B, Andridge R, Anderson SE, **Crandall WV**. Variation in management of intra-abdominal abscesses in children with Crohn's disease. Inflamm Bowel Dis. 2013 Mar;19(4):818-25.
- 60. Perez ME, Coley B, **Crandall W**, Di Lorenzo C, Bravender T. Effect of Nutritional Rehabilitation on Gastric Motility and Somatization in Adolescents with Anorexia. J Pediatr 2013;163:867-72).
- 61. Brilli RJ, McClead RE Jr, Crandall WV, Stoverock L, Berry JC, Wheeler TA, Davis JT. A Comprehensive Patient Safety Program Can Significantly Reduce Preventable Harm, Associated Costs and Hospital Mortality. J Pediatr. 2013 Dec;163(6):1638-45
- 62. **Crandall, W**. (2013). T3 Translational Science in Gastroenterology: Getting to Best Outcomes. *Clinical Gastroenterology and Hepatology*, 11(12), 1559-1561.
- 63. Walters, T. D., Kim, M., Denson, L. A., Griffiths, A. M., Dubinsky, M., Markowitz, J., Baldassano R, **Crandall W**... & Hyams, J. S. (2013). Increased Effectiveness of Early Therapy with Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease. *Gastroenterology*. 2014 Feb;146(2):383-91.
- 64. **Crandall, W. V.,** Baldassano, R., Bousvaros, A., Denson, L. A., Gupta, N., & Mackner, L. M. (2014). NASPGHAN Single-Topic Symposium: Discovering the Future of Pediatric IBD Care. *J Pediatr Gastroenterol Nutr*, *58*(1), 130-138.
- 65. Park, K. T., **Crandall, W. V.**, Fridge, J., Leibowitz, I. H., Tsou, M., Dykes, D. M., ... & Colletti, R. B. (2014). Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. *Vol. 20, no. 5. (May 2014): 946-951*
- 66. Walters, T. D., Kim, M. O., Denson, L. A., Griffiths, A. M., Dubinsky, M., Markowitz, J.,... Crandall W. V. ... & Hyams, J. S. (2014). Increased Effectiveness of Early Therapy With Anti–Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology, 146(2), 383-391.
- 67. Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., ... Crandall W., ... & Xavier, R. J. (2014). The Treatment-Naive Microbiome in New-Onset Crohn's Disease. *Cell Host & Microbe*, 15(3), 382-392.
- 68. Minar, P., Haberman, Y., Jurickova, I., Wen, T., Rothenberg, M. E., Kim, M. O., ... Crandall W,... & Denson, L. A. (2014). Utility of Neutrophil Fcγ Receptor I (CD64) Index as a Biomarker for Mucosal Inflammation in Pediatric Crohn's Disease. *Inflamm Bowel Dis.* 2014 Jun; 20(6):1037-48

- 69. Lee, G. J., Dotson, J. L., Kappelman, M. D., King, E., Pratt, J. M., Colletti, R. B., ... & Crandall, W. V. (2014). Seasonality and Pediatric Inflammatory Bowel Disease: A Multicenter Experience. *J Pediatr Gastroenterol Nutr*.
- 70. Forrest, C. B., **Crandall, W. V.**, Bailey, L. C., Zhang, P., Joffe, M. M., Colletti, R. B., ... & Kappelman, M. D. (2014). Effectiveness of anti-TNFα for Crohn disease: research in a pediatric learning health system. *Pediatrics*. 2014 Jul; 134(1):37-44.
- 71. Boyle, B. M., Kappelman, M. D., Colletti, R. B., Baldassano, R. N., Milov, D. E., & Crandall, W. V. (2014). Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. *World J Gastroenterol.* 2014 Jul 21;20(27):9185-90
- 72. Haberman, Y., Tickle, T. L., Dexheimer, P. J., Kim, M. O., Tang, D., Karns, R., ... Crandall W.,... & Denson, L. A. (2014). Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. *J Clin Invest.* 2014 *Aug*;124(8):3617-33.
- 73. Brilli, R. J., **Crandall, W. V.,** Berry, J. C., Stoverock, L., Rosen, K., Budin, L., ... & Davis, J. T. (2014). A Patient/Family-Centered Strategic Plan Can Drive Significant Improvement. *Adv Pediatr.* 2014 Aug;61(1):197-214
- 74. Dotson JL, **Crandall WV**, Zhang P, Forrest CB, Bailey LC, Colletti RB, Kappelman MD. (2014). Feasibility and Validity of the Pediatric Ulcerative Colitis Index in Routine Clinical Practice. *J Pediatr Gastroenterol Nutr*. 2015 Feb;60(2):200-4
- 75. Pusateri AJ, Kim SC, Dotson JL, Balint JP, Potter CJ, Boyle BM, **Crandall WV**. Incidence, Pattern and Etiology of Elevated Liver Enzymes in Pediatric Inflammatory Bowel Disease: A Single Center Experience. *J Pediatr Gastroenterol Nutr*. 2015 May;60(5):592-7
- 76. Dotson JL, Kappelman MD, Chisolm DJ, **Crandall WV**. Racial Disparities in Readmission, Complications and Procedures in Children with Crohn's Disease. *Inflamm Bowel Dis.* 2015 Apr;21(4):801-8
- 77. Dotson JL, Bashaw H, Nwomeh B, **Crandall WV**. Management of Intra-Abdominal Abscesses in Children With Crohn's Disease: A 12-Year Retrospective Single Center Review. *Inflamm Bowel Dis.* 2015 May;21(5):1109-14
- 78. Hommel KA, Gray WN, **Crandall W**, Denson LA. The Telehealth Enhancement of Adherence to Medication in Pediatric IBD (TEAM) Trial: Design and Methodology. *Contemp Clin Trials*. 2015 Jul;43:105-13.
- 79. Cutler DJ, Zwick ME, ... **Crandall WV**, ... Denson LA. Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping. *PLoS One*. 2015 Jun 22;10(6):e0128074

- 80. Van Limgergen J, Haskett J, ... **Crandall W**, ... Otley AR. Toward Enteral Nutrition for the Treatment of Pediatric Crohn Disease in Canada: A Workshop to Identify Barriers and Enablers. *Can J Gastroenterol Hepatol*. 2015 Oct;29(7):351-6.
- 81. Dotson JL, Bricker JB, Kappelman MD, Chisolm D, **Crandall WV**. Assessment of Sex Differences for Treatment, Procedures, Complications and Associated Conditions Among Adolescents Hospitalized with Crohn's Disease. *Inflamm Bowel Dis.* 2015 Nov;21(11):2619-24
- 82. Livshits, A., Fisher, D., Hadas, I., Bdolah-Abram, T., Mack, D., Hyams, J., ... Crandall W... & Turner, D. (2016). Abdominal X-ray in Pediatric Acute Severe Colitis and Radiographic Predictors of Response to Intravenous Steroids. *Journal of pediatric gastroenterology and nutrition*, 62(2), 259-263.
- 83. Ardura, M. I., Toussi, S. S., Siegel, J. D., Lu, Y., Bousvaros, A., & Crandall W. (2016). NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-Alpha Inhibitors. *Journal of pediatric gastroenterology and nutrition*, 63(1), 130-155.
- 84. Donegan, A., Boyle, B., **Crandall W.**, Dotson, J. L., Lemont, C., Moon, T., & Kim, S. C. (2016). Connecting Families: A Pediatric IBD Center's Development and Implementation of a Volunteer Parent Mentor Program. *Inflammatory bowel diseases*, 22(5), 1151-1156.
- 85. Marigorta, U. M., Denson, L. A., Hyams, J. S., Mondal, K., Prince, J., Walters, T. D., ... Crandall W,...& Mack, D. R. (2017). Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease. *Nature genetics*, . 49(10), 1517
- 86. Kugathasan, S., Denson, L. A., Walters, T. D., Kim, M. O., Marigorta, U. M., Schirmer, M., ... Crandall, W. V... Dubinsky M.C. (2017). Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. *The Lancet*, 389(10080), 1710-1718.
- 87. Rosen, M. J., Karns, R., Vallance, J. E., Bezold, R., Waddell, A., Collins, M. H., ... **Crandall, W. V...**Denson L.A. (2017). Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. *Gastroenterology*, *152*(6), 1345-1357.
- 88. Ellery, K. M., Kumar, S., **Crandall, W.,** & Gariepy, C. (2017). The benefits of early oral nutrition in mild acute pancreatitis. *The Journal of pediatrics*, *191*, 164-169.
- 89. Dotson, J. L., Cho, M., Bricker, J., Kappelman, M. D., Chisolm, D. J., Tomer, G., ... **Crandall, W. V.** & ImproveCareNow Pediatric IBD Learning Health System. (2017). Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn's Disease: Results from the ImproveCareNow Network. *Inflammatory bowel diseases*, 23(5), 767-774.

- 90. **Crandall, W.,** Davis, J. T., Dotson, J., Elmaraghy, C., Fetzer, M., Hayes, D., ... & Brilli, R. J. (2018). Clinical Indices Can Standardize and Monitor Pediatric Care: A Novel Mechanism to Improve Quality and Safety. *The Journal of pediatrics*, 193, 190-195.
- 91. Haberman, Y., BenShoshan, M., Di Segni, A., Dexheimer, P. J., Braun, T., Weiss, B., ... Crandall, W.; ... & Rosh, J. (2018). Long ncRNA Landscape in the Ileum of Treatment-Naive Early-Onset Crohn Disease. *Inflammatory Bowel Diseases*, 24(2), 346-360.
- 92. Bartman, T., Heiser, K., Bethune, A., Crandall, W., McClead, R., Davis, J. T., & Brilli, R. J. (2018). Interprofessional QI Training Enhances Competency and QI Productivity Among Graduates: Findings From Nationwide Children's Hospital. *Academic Medicine*, 93(2), 292-298.
- 93. Shaw, K. A., Cutler, D. J., Okou, D., ... **Crandall, W**.; ... & Noe, J. D. (2018). Genetic variants and pathways implicated in a pediatric inflammatory bowel disease cohort. *Genes & Immunity*, E pub Ahead of Print
- 94. Chandradevan, R., Hofmekler, T., Mondal, K., ... **Crandall, W. V.**; ... Kugathasan S. (2018). Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles. *Inflammatory bowel diseases*. E Pub Ahead of Print
- 95. Serpico, M. R., Maltz, R., **Crandall, W**., Bricker, J., Dotson, J. L., Kim, S. C., & Boyle, B. (2018). Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. *Journal of pediatric gastroenterology and nutrition*, 67(3), 341-345.
- 96. Denson, L. A., Jurickova, I., Karns, R., ... **Crandall W. V.,** ... Kugathasan S. (2018). Clinical and Genomic Correlates of Neutrophil Reactive Oxygen Species Production in Pediatric Patients With Crohn's Disease. *Gastroenterology*, 154(8), 2097-2110.
- 97. Lindoso, L., Mondal, K., Venkateswaran, S., Somineni, H. K., Ballengee, C., Walters, T. D., ... **Crandall W.V.** ... & Ananthakrishnan, A. N. (2018). The effect of early-life environmental exposures on disease phenotype and clinical course of Crohn's disease in children. *Official journal of the American College of Gastroenterology* | ACG, 113(10), 1524-1529.
- 98. Shaikhkhalil, A. K., Boyle, B., Smith, J., Dotson, J. L., Donegan, A., Kim, S. C., ... & Crandall, W. (2018). Using Quality Improvement to Increase Utilization of Enteral Therapy in Pediatric Crohn Disease: Results and Outcomes. *Journal of pediatric gastroenterology and nutrition*, 66(6), 909-914.
- 99. Shaikhkhalil, A. K., & Crandall, W. (2018). Enteral nutrition for pediatric Crohn's disease: an underutilized therapy. *Nutrition in Clinical Practice*, *33*(4), 493-509.

- 100. Dotson, J. L., Kappelman, M. D., Bricker, J., Andridge, R., Chisolm, D. J., & Crandall, W. V. (2019). Multicenter evaluation of emergency department treatment for children and adolescents with Crohn's disease according to race/ethnicity and insurance payor status. *Inflammatory Bowel Diseases*, 25(1), 194-203.
- 101. Pratt, J., Jeffers, D., King, E. C., Kappelman, M. D., Collins, J., Margolis, P., ... **Crandall W. V.** ... & Wali, P. D. (2019). Implementing a novel quality improvement-based approach to data quality monitoring and enhancement in a multipurpose clinical registry. *eGEMs*, 7(1).
- 102. Somineni, H. K., Venkateswaran, S., Kilaru, V., Marigorta, U. M., Mo, A., Okou, D. T., ... **Crandall W.V.** ... & Kugathasan, S. (2019). Blood-derived DNA methylation signatures of Crohn's disease and severity of intestinal inflammation. *Gastroenterology*, 156(8), 2254-2265.
- 103. Wu, J., Lubman, D. M., Kugathasan, S., Denson, L. A., Hyams, J. S., Dubinsky, M. C., ... Crandall W.V. ... & Stidham, R. W. (2019). Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease. *The American journal of gastroenterology*, 114(5), 777.
- 104. Haberman, Y., Schirmer, M., Dexheimer, P. J., Karns, R., Braun, T., Kim, M. O., ... Crandall W. V. ... & Denson, L. A. (2019). Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis. *Mucosal immunology*, 12(2), 491-502.
- 105. Krishnakumar, C., Ballengee, C. R., Liu, C., Kim, M. O., Baker, S. S., Baldassano, R. N., ... **Crandall W. V.** ... & Kugathasan, S. (2019). Variation in care in the management of children with Crohn's disease: data from a multicenter inception cohort study. *Inflammatory bowel diseases*, 25(7), 1208-1217.
- 106. Gettler, K., Giri, M., Kenigsberg, E., Martin, J., Chuang, L. S., Hsu, N. Y., ... **Crandall W. V.** ... & Cho, J. H. (2019). Prioritizing Crohn's disease genes by integrating association signals with gene expression implicates monocyte subsets. *Genes & Immunity*, 20(7), 577-588.
- 107. Lee, R., Maltz, R. M., Crandall, W. V., Plogsted, S. W., Shaikhkhalil, A. K., Bowden, S. A., & Mezoff, E. A. (2020). Single high-dose vitamin D3 supplementation in pediatric patients with inflammatory bowel disease and hypovitaminosis D. *Journal of pediatric gastroenterology and nutrition*, 70(4), e77-e80.
- 108. Balch Samora, J., Spencer, S. P., Valleru, J., Bartman, T., Brilli, R. J., Davis, M., ... & Crandall, W. (2020). Writing group increases quality improvement writing competency. *American Journal of Medical Quality*, *35*(4), 349-354.

- 109. Noel, G. J., DeBiasi, R. L., **Crandall, W.**, & Connor, E. M. (2021). Ensuring continued progress for development of COVID-19 therapeutics in children. *Pediatric Research*, 90(6), 1112-1114.
- 110. Mulberg, A. E., Conklin, L. S., Croft, N. M., Parikh, A., Bousvaros, A., DeZoeten, E., ... **Crandall W. V.** ... & Hovinga, C. (2022). Pediatric extrapolation of adult efficacy to children is critical for efficient and successful drug development. *Gastroenterology*, 163(1), 77-83.
- 111. Nelson, R. M., Conklin, L. S., Komocsar, W. J., Chen, F., Williamson, F., & Crandall, W. V. (2022). The role of master protocols in pediatric drug development. *Therapeutic Innovation & Regulatory Science*, 56(6), 895-902.
- 112. Hunter, T., Komocsar, W. J., Liu, C., Colletti, R. B., Steiner, S. J., Dotson, J. L., ... & Crandall, W. (2022). Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study. *Crohn's & Colitis 360*, 4(2), otac009.
- 113. Brunner, H. I., Vadhariya, A., Dickson, C., **Crandall, W.,** Choong, C. K. C., Birt, J. A., ... & Ramanan, A. V. (2023). Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. *Lupus Science & Medicine*, 10(2), e000817.
- 114. Hunter, T., Komocsar, W. J., Colletti, R. B., Liu, C., Benkov, K. J., Dotson, J. L., ... & **Crandall W. V.** for the ImproveCareNow Network. (2023). Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease. *Current Medical Research and Opinion*, 39(1), 63-69.
- 115. Croft, N. M., de Ridder, L., Griffiths, A. M., Hyams, J. S., Ruemmele, F. M., Turner, D., ... **Crandall W. V.** ... & Vassal, G. (2023). Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents. *Journal of Crohn's and Colitis*, 17(2), 249-258.

REVIEWS AND ABSTRACTS (Selected reviews and abstracts through 2017 only)

- 1. **Crandall W**, Norlin C, Bulock EA, Shearrow ME, Tani LY, Orsmond GS, Shaddy RE. Etiology and Outcome of Outpatient Fevers in Pediatric Heart Transplant Patients. Pediatric Research 1996;35(9):437-42
- 2. **Crandall W**, Lowe ME. Site Directed Mutagenesis of Colipase Reveals Specific Residues that Control the Digestion of Dietary Fat by Pancreatic Triglyceride Lipase. Gastroenterology 2000;118(4):1236A.

- 3. **Crandall W**, Lowe ME. Site Directed Mutagenesis of Colipase Reveals Specific Residues that Control Lipase Mediated Dietary Fat Digestion Through a Bile Salt Micelle Dependent Mechanism. J Pediatr Gastroenterol Nutr 2000;31:895A.+
- 4. Erdman SH, **Crandall W**. Pediatric Gastroesophageal Reflux: Mere Inconvenience or Real Disease? Pediatric Directions 2001 Fall:14-17.
- 5. **Crandall W**, Mackner L. Adverse Reactions in Children and Adolescents Following Infliximab Infusions. Gastroenterology 2002;122(4 supplement):A-614.
- 6. Moulton DE, **Crandall W**, Lowe ME. Expression of a Novel Cadherin in the Developing Intestine. Gastroenterology 2002;122(4 supplement):A-374.
- 7. Mackner LM, **Crandall W**. Coping Strategies and Social Support in Pediatric Inflammatory Bowel Disease: Preliminary Results. J Pediatr Gastroenterol Nutr 2002;35(3):21A.
- 8. Mackner LM, **Crandall W**. Eating Behaviors in Mild to Quiescent Pediatric Inflammatory Bowel Disease: Preliminary Results. J Pediatr Gastroenterol Nutr 2002;35(3):23A.
- 9. Mackner LM, **Crandall W**. Psychosocial Outcomes in Mild Pediatric Inflammatory Bowel Disease. Gastroenterology 2003; 124 (supp. 1), A212-A213.
- 10. Mackner LM, **Crandall W**. Quality of Life in Pediatric Inflammatory Bowel Disease: Predictors and Comparisons with Healthy and Other Disease Populations. Gastroenterology 2003; 124 (suppl.1), A209.
- 11. Erdman SH, **Crandall W**. Pediatric Gastroesophageal Reflux: Mere Inconvenience or Real Disease? Columbus Physician 2003 Spring: 14-17.
- 12. Mackner LM, **Crandall W**. Gender Differences in Weight and Body Image Contribute to Problematic Eating Behaviors in Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2003; 37, 375
- 13. Mackner LM, **Crandall W**. Predictors of Behavioral/Emotional Functioning in Children with Inflammatory Bowel Disease Compared to Healthy Children. J Pediatr Gastroenterol Nutr 2003; 37, 375
- 14. Mackner LM, **Crandall W**. Oral Medication Adherence in Pediatric Inflammatory Bowel Disease J Pediatr Gastroenterol Nutr 2004; 39, S314.
- 15. Mackner LM, **Crandall W**. Steroid Treatment Impairs Memory in Pediatric Inflammatory Bowel Disease. Gastroenterology 2005;128 (4, Suppl 2) A-166-7.

- 16. **Crandall W**, Halterman T, Mackner LM. Differential Effect of Anxiety and Pain Perception in Children with IBD and Functional Gastrointestinal Disorders Undergoing Colonoscopy. J Pediatr Gastroenterol Nutr 2005; 41, 541.
- 17. Punati JB, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, **Crandall W**. Early Immunomodulator use Improves 18 Month Outcomes in Pediatric Crohn's Disease. Gastroenterology 2006; 130 (4, Suppl 2) 949-54.
- 18. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Trevers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Maintenance Therapy with Infliximab Every 8 Weeks is Superior to Every 12 Weeks in Maintaining Response and Remission in Pediatric Patients with Moderately to Severely Active Crohn's Disease. Gastroenterology 2006; 130 (4, Suppl 2) A-12.
- 19. Griffiths A, Hyams J, Crandall W, Kugathasan S, Olson A, Johanns J, Liu G, Raychaudhuri A, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Height of Growth Delayed Children with Active Crohn's Disease Improves During Treatment with Infliximab. Gastroenterology 2006; 130 (4, Suppl 2) A-12.
- 20. Pfefferkorn M, Hyams J, Burke G, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer S, Rothbaum R, Wyllie R, Tolia V, Oliva-Hemker M, Mezoff A, Leleiko N, DelRosario F, **Crandall W**, Keljo D, Baldassano R. Griffiths A. Growth Failure Persists Despite Current Treatment Paradigms in Pediatric Crohn's Disease. Gastroenterology 2006; 130 (4, Suppl 2) A-191.
- 21. Rosh J, Hyams J, Lerer T, Markowitz J, Pfefferkorn M, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer S, Rothbaum R, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, DelRosario F, **Crandall W**, Keljo D, Baldassano R, Griffiths A. Outcome of Moderate to Severe Pediatric Crohn's Disease: Effect of Infliximab Therapy. Gastroenterology 2006; 130 (4, Suppl 2) A-192.
- 22. Sharrett MK, Russo JM, **Crandall WV**. An Analysis of Celiac Disease: Diagnosis and Treatment. Pediatric Directions 2006; (Summer, 29):12-16.
- 23. Mackner LM, **Crandall WV**. Concordance Among Physician, Parent and Child Report of Symptoms in Adolescents with Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2006; 43 E48.
- 24. **Crandall WV**, Hyams J, Kugathasan S, Griffiths A, Livingston J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Reduction in Fistula in Infliximab Treated Patients: Observations from REACH. J Pediatr Gastroenterol Nutr 2006; 43 E47.

- 25. Keljo D, Markowitz J, Langton C, Lerer T, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer S, Rothbaum R, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, DelRosario F, **Crandall W**, Hyams J. Perianal Fistulae in Pediatric Crohn Disease: Therapies and Course. J Pediatr Gastroenterol Nutr 2006; 43 E51.
- 26. Markowitz J, Hyams J, Lerer T, Mack D, Evans J, Rosh J, Griffiths A, Kugathasan S, Otley A, Pfefferkorn M, Keljo D, Leleiko N, Bousvaros A, Crandall W, Moyer S, Rothbaum R, Wyllie R, Oliva-Hemker M, DelRosario F, Mezoff A. Does Age at Onset Affect IBD Treatment? J Pediatr Gastroenterol Nutr 2006; 43 E48.
- 27. Keljo D, Markowitz J, Langton C, Lerer T, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer S, Rothbaum R, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, **Crandall W**, Hyams J. Fistulae in Pediatric Crohn Disease: Frequency and Time Course. Gastroenterology 2007; 132 (4 Suppl 2) A-654.
- 28. Markowitz J, Rosh J, Pfefferkorn M, Otley A, Oliva-Hemker M, Moyer S, Mack D, Leleiko N, Kugathasan S, Evans J, **Crandall W**, Langton S, Hyams J. Young Children with Crohn Disease Demonstrate Different Serologic Profiles Than Those Who Present at an Older Age. Gastroenterology 2007; 132 (4 Suppl 2) A-173.
- 29. Markowitz J, **Crandall W**, Evans J, Kugathasan S, Leleiko N, Mack D, Moyer S, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Langton C, Hyams J. Anti-cBirl is Helpful in Characterizing Children with Indeterminate Colitis. Gastroenterology 2007; 132 (4 Suppl 2) A-363.
- 30. Moy L, Markowitz J, Mack D, Evans J, Leleiko N, Kugathasan S, Pfefferkorn M, Rosh J, Otley A, **Crandall W**, Griffiths A, Oliva-Hemker M, Keljo D, Mezoff A, Moyer S, Bousvaros A, Wyllie R, Langton C, Hyams J. Clinical Outcome of Ulcerative Colitis (UC) in Children: A Prospective 3 year Follow-Up from Diagnosis. Gastroenterology 2007; 132 (4 Suppl 2) A-516.
- 31. Dubinsky M, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Oliva-Hemker M, Leleiko N, **Crandall W**, Langton C, Taylor K, Targan S, Rotter J, Markowitz J, Hyams J. Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Gastroenterology 2007; 132 (4 Suppl 2) A-17.
- 32. Otley A, Markowitz J, Lerer T, Griffiths A, Moyer S, Leleiko N, Evans J, Mack D, Rosh J, Pfefferkorn M, Kugathasan S, Keljo D, Baldassano R, Kay M, Oliva-Hemker M, Bousvaros A, **Crandall W**, Carvalho R, Hyams J. Budesonide Use at Diagnosis in a Large Multi-Center Prospective Pediatric Cohort. J Pediatr Gastroenterol Nutr 2007; 45 E79.
- 33. Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer S, Wyllie R, Oliva-Hemker M, Carvalho R, **Crandall**

- **W**, Keljo D, Walters T, Leleiko N, Hyams J. Effect of Current Treatment Paradigms on Growth in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr 2007; 45 E78.
- 34. Greifer, M, Kugathasan S, Hyams J, Leleiko N, Mack D, Griffiths A, Crandall W, Bousvaros A, Evans J, Moyer S, Rosh J, Otley A, Pfefferkorn M, Oliva-Hemker M, Keljo D, Carvalho R, Kay M, Baldassano R, Lerer T, Markowitz J. IBD Activity at Initial Diagnosis: Effect of Body Mass Index. J Pediatr Gastroenterol Nutr 2007; 45 E5.
- 35. Kappelman, M, Margolis, P, Moyer M, Cohen S, Gold B, **Crandall W**, Patel A, Mehta D, Milov D, Grunow J, Leibowitza I, Colletti R. The Quality of Care in Pediatric Inflammatory Bowel Disease: Does the Chronic Care Model work? J Pediatr Gastroenterol Nutr 2007; 45 E5.
- 36. Hyams J, Lerer T, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Griffiths A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Moyer S, Kay M, **Crandall W**, Oliva-Hemker M, Keljo D, Leleiko N, Markowitz J. Long Term Outcome Following Infliximab Therapy in Pediatric Patients with Crohn Disease: Results from a Multicenter Study. Gastroenterology 2008; 134 (4 Suppl 1) A-134.
- 37. Schaefer M, Hyams J, Markowitz J, Mack D, Griffiths A, Otley A, Bousvaros A, Keljo D, Evans J, Pfefferkorn M, Kay M, Mamula P, Rosh J, Carvalho R, Kugathasan S, Moyer S, **Crandall W**, Leleiko N. Surgery in a Prospectively Followed Cohort of Pediatric Patients with Crohn's Disease. Gastroenterology 2008; 134 (4 Suppl 1) A-498.
- 38. Markowitz J, Kugathasan S, Dubinsky M, Ling M, **Crandall W**, Leleiko N, Oliva-Hemker M, Rosh J, Evans J, Mack D, Otley A, Pfefferkorn M, Bahar R, Vasiliauskas E, Wahbeh G, Silber G, Quiros A, Wrobel I, Nebel J, Landers C, Picornell Y, Taylor K, Rotter J, Targan S, Hyams J. Age of Diagnosis Influences Serologic Responses in Children with Crohn Disease: A Possible Clue to Etiology? Gastroenterology 2008; 134 (4 Suppl 1) A-54.
- 39. Kappelman M, Cohen S, **Crandall W**, Duffy L, Gold B, Grunow J, Kim S, Leibowitz I, Margolis P, Mehta D, Milov D, Moyer S, Myers S, Patel A, Schoen B, Sudel B, Colletti R. Accelerating Improvement in the Management of Pediatric Inflammatory Bowel Disease. Gastroenterology 2008; 134 (4 Suppl 1) A-473.
- 40. Dotson J, Hyams J, Markowtiz J, Leleiko N, Mack D, Evans J, Pfefferkorn M, Griffiths A, Otley A, Bousvaros A, Kugathasan S, Rosh J, Keljo D, Carvalho R, Moyer S, Mamula P, Kay M, Kerzner B, Langton C, **Crandall W**. Extra-Intestinal Manifestations of Pediatric Inflammatory Bowel Disease. Gastroenterology 2008; 134 (4 Suppl 1) A-639.
- 41. Rosh J, Lerer T, Markowitz J, Goli S, Mamula P, Noe J, Pfefferkorn M, Kelleher K, Griffiths A, Kugathasan S, Keljo D, Oliva-Hemker M, **Crandall W**, Carvalho R, Mack D, Hyams J. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease. Gastroenterology 2008; 134 (4 Suppl 1) A-657.

- 42. Bousvaros A, Lerer T, Markowitz J, Griffiths A, Keljo D, Leleiko N, Mack D, Evans J, Pfefferkorn M, Otley A, Kugathasan S, Rosh J, Carvalho R, Moyer S, Kay M, Mamula P, Kerzner B, **Crandall W**, Hyams J. Clinical Outcome Following Immunomodulator Therapy in Pediatric Ulcerative Colitis: Results from a Prospective Multicenter Inception Cohort. Gastroenterology 2008; 134 (4 Suppl 1) A-639.
- 43. Otley A, Markowitz J, Leleiko N, Griffiths A, **Crandall W**, Kugathasan S, Oliva-Hemker M, Bousvaros A, Pfefferkorn M, Mack D, Evans J, Rosh J, Keljo D, Mamula P, Moyer S, Carvalho R, Kerzner B, Kay M, Lerer T, Hyams J. Budesonide is an Effective but Underutilized Therapy in Pediatric Crohn Disease. Gastroenterology 2008; 134 (4 Suppl 1) W1225.
- 44. Kappelman MD, Cohen SA, **Crandall W**, Duffy L, Gold B, Grunow J, Kim S, Leibowitz I, Margolis P, Mehta D, Milov D, Moyer S, Myers S, Patel A, Schoen B, Sudel B, Bornstein J, Colletti R. Improving Care of Pediatric Inflammatory Bowel: Preliminary Results of a Multicenter Improvement Collaborative. E-PAS2008:5625.
- 45. Hyams J, Crandall W, Kugathasan S, Griffiths A, Blank M, Lang G, Heuschkel R, Veereman-Wauters G, Baldassano R. Disease Duration Does Not Affect Outcome Following Infliximab Therapy in Children With Crohn's Disease. Am J Gastroenterol 2008; 103 (S1) S533.
- 46. Patel AS, Kim S, Kappelman M, Colletti R, Cohen S, Grunow J, **Crandall W**, Duffy L, Gold B, Leibowitz I, Margolis P, Mehta D, Milov D, Moyer S, Myers S, Schoen B, Sudel B, Bornstein J. Growth Failure in a Pediatric Inflammatory Bowel Disease Registry (PIBDNet) with Specific Association to Disease Phenotype. Journal of Pediatric Gastroenterology, Hepatology, and Nutrition [JPGN web site]. Available at: http://www.jpgn.org/pt/pt-core/template-journal/jpgn/media/resumos.pdf.
- 47. Hyams J, Lerer T, Griffiths A, Evans J, Carvalho R, Otley A, Bousvaros A, Mack D, Pfefferkorn M, Rosh J, Kay M, **Crandall W**, Tomer G, Leleiko N, Keljo D, Markowitz J. Outcome Following Infliximab Therapy in Pediatric Patients with Ulcerative Colitis: Results from a Multicenter Study. Gastroenterology 2009; 136 (Suppl 1) W1187.
- 48. Markowitz J, Mack D, Leleiko N, Otley A, Evans J, Pfefferkorn M, Oliva-Hemker M, Crandall W, Rosh J, Kappelman M, Keljo D, Kugathasan S, Lerer T, Hyams J. Anti-Cbirl is Commonly Detectable in Children with Ulcerative Colitis, but Does Not Predict Disease Course Over the First 2 Years of Treatment. Gastroenterology 2009; 136 (Suppl 1) W1103.
- 49. Kappelman M, Markowitz J, Bousvaros A, Carvalho R, **Crandall W**, Evans J, Galanko J, Griffiths A, Keljo D, Kugathasan S, Langton C, Leleiko N, Mack D, Otley A, Pfefferkorn M, Rosh J, Tomer G, Hyams J. Inter-Center Variation in the Clinical Outcomes of Pediatric Crohn's Disease. Gastroenterology 2009; 136 (Suppl 1) 154.

- 50. Siegel C, Siegel L, Hyams J, Kugathasan S, Markowitz J, Rosh J, Leleiko N, Mack D, Crandall W, Evans J, Keljo D, Otley A, Oliva-Hemker M, Langton C, Wrobel I, Wahbeh G, Quiros A, Silber G, Bahar R, Sands B, Dubinsky M. A Prediction Tool to Help Children with Crohn's Disease and their Parents Understand Individualized Risks of Disease Complications and Response to Therapy. Gastroenterology 2009; 136 (Suppl 1) 1108.
- 51. Lora M, Pfefferkorn M, Langton C, Markowitz J, Evans J, Rosh J, Kay M, Crandall W, Keljo D, Otley A, Kugathasan S, Carvalho R, Oliva-Hemker M, Bousvaros A, Leleiko N, Mack D, Griffiths A, Hyams J. Indeterminate Colitis (IC) In Children: A Two-Year Follow-Up. Gastroenterology 2009; 136 (Suppl 1) W1189.
- 52. Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, **Crandall W**, Markowitz J, Otley A, Xu W, Hu P, Griffiths A, Silverberg M. Gene Expression Profiles Associated with Lack of Response to Intravenous Corticosteroids in Children with Severe Ulcerative Colitis. Gastroenterology 2009; 136 (5 Suppl 1):A-172 (Abst 1107).
- 53. Kusek K, Crandall W, Nicol K, Mackner L, Potter C. Anti-Smooth-Muscle and Anti-Nuclear Antibodies do not Correlate with Increasing Severity of Liver Inflammation and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology 2009; 136 (Suppl 1) T1122.
- 54. Rosh J, Mohamed A, Markowitz J, Mack D, Griffiths A, Bousvaros A, Kay M, Mamula P, Pfefferkorn M, Carvalho R, Kugathasan S, Keljo D, Tomer G, Leleiko N, Oliva-Hemker M, Lerer T, Hyams J, **Crandall W**. Utilization and Effect of Methotrexate in the Treatment of Pediatric Crohn's Disease: A Multi-Center Experience. Gastroenterology 2009; 136 (Suppl 1) W1196.
- 55. Kusek K, Punati J, Bevins C, Barnard J, Kays R, Chu H, Mackner L, **Crandall W.** Human Alpha Defensin 5 mRNA Levels are Decreased in Children with Untreated, Newly Diagnosed Crohn's Disease. Gastroenterology 2009; 136 (Suppl 1) 77.
- 56. Turner D, Mack D, Uusoue K, Hyams J, Leleiko N, Leach S, Walters T, Day A, **Crandall W**, Markowitz J, Silverberg M, Otley A, Mamula P, Griffiths A. A Prospective Multicenter Study of Outcomes and Predictors of Response in Severe Pediatric Ulcerative Colitis. Gastroenterology 2009; 136 (5 Suppl 1):A-571 (Abst T1745).
- 57. Oliva-Hemker M, Hutfless S, Hyams J, Langton C, Lerer T, Bousvaros A, Carvalho R, Crandall W, Evans J, Griffiths A, Kay M, Keljo D, Kugathasan S, LeLeiko N, Mack D, Mamula P, Otley A, Pfefferkorn M, Rosh J, Markowitz J. Medication Use and Disease Characteristics in Early-Onset and Later-Onset Pediatric Inflammatory Bowel Disease (IBD). Gastroenterology 2009; 136 (Suppl 1) W1198.

- 58. Boyle B, Mackner L, Ross C, Kumar S, Moses J, Crandall W. Single-Center Experience with Methotrexate after Thiopurine Therapy in Pediatric Crohn's Disease. Gastroenterology 2009; 136 (Suppl 1) w1203.
- 59. Turner D, Wine E, **Crandall W**, Kolho K, Mack D, Hyams J, Silverberg MS, Otley AR, Markowitz J, Leleiko N, Leach, Griffiths AM. Determinants of Corticosteroids Resistance in Severe Pediatric Ulcerative Colitis: a Transitional Prospective Study. Inflamm Bowel Dis 2009; 5 (12 Suppl):S16 (Abstr P-38).
- 60. Hyams J, Blank M, Johanns J, **Crandall W**, Kugathasan S, Griffiths A, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman G, Ferry G, Walters T, Baldassano R. Long-Term Efficacy and Safety of Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease. Gastroenterology 2009; 136 (Suppl 1) W1181 A671-2.
- 61. Keljo D, Markowitz J, Langton C, Lerer T, Bousvaros A, Carvalho R, Crandall W, Evans J, Griffiths A, Kay M, Kugathasan S, Leleiko N, Mack D, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Tomer G, Hyams J. Growth in Pediatric Patients with IBD Treated with Infliximab or Mercaptopurine/Azathioprine. Gastroenterology 2009; 136 (Suppl 1) W1188.
- 62. Joel R. Rosh, Trudy Lerer, James Markowitz, Petar Mamula, Marian D. Pfefferkorn, Anne M. Griffiths, Subra Kugathasan, David Keljo, Maria Oliva-Hemker, Wallace Crandall, Ryan Carvalho, David Mack, Jeffrey Hyams. Long Term Use of Adalimumab in Pediatric Crohn's Disease: A Multi-Center Study. Am J Gastroenterol 2009;104:S-548.
- 63. **Crandall W**, Kappelman M, Colletti RB, Denson L, Duffy L, Grunow J, Kim S, Leibowitz I, Patel A, Schoen B, Tomer G, Milov D, Cohen S, Margolis P, and the ImproveCareNow Collaborative (formerly PIBDNet), Burlington, VT, USA. Increased Remission in a Quality Improvement Collaborative for Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2009; 135 (49) Suppl 1: E60.
- 64. Otley A, Markowitz J, Lerer T, Griffiths A, Evans J, Stephens M, Bousvaros A, Mack D, Carvalho R, Pfefferkorn M, Rosh J, Kay M, Oliva-Hemker M, Tomer G, LeLeiko N, Crandall W, Grossman A, Keljo D, Kerzner B, Saeed S, Kappelman M, Faubion W, Kugathasan S, Langton C, Hyams J. Budesonide Monotherapy Uncommon in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2009; 142 (49) Suppl 1:E63.
- 65. Kappelman M, Goudie A, **Crandall W**, Larry E, Fairbrother G, Margolis P, Leibowitz I, Duffy L, Milov D, Kim S, Schoen B, Cohen S, Patel A, Grunow J, Colletti R. A Rapid Pediatric Crohn's Disease Activity Index for Quality Improvement and Observational Research. J Pediatr Gastroenterol Nutr 2009; 196 (49) Suppl 1:E87.

- 66. Punati J, Bedrnicek J, Kusek K, **Crandall W**, Mousa H, DiLorenzo C. Comparison of Mucosal Mast Cell Numbers in Patients with Irritable Bowel Syndrome, Crohn disease and Controls. J Pediatr Gastroenterol Nutr 2009; 125 (49) Suppl 1: E55.
- 67. Markowitz J, LeLeiko N, Keljo D, **Crandall W**, Mack D, Evans J, Kappelman M, Pfefferkorn M, Otley A, Oliva-Hemker M, Kugathasan S, Rosh J, Tomer G, Carvalho R, Langton C, Hyams J. Value of the Prometheus Smart Diagnostic Algorithm for Differentiating CD from UC in Children with IBD. J Pediatr Gastroenterol Nutr 2009; 202 (49) Suppl 1:E90.
- 68. Hardin D, **Crandall W**. Poor Growth in Crohn's Disease is Caused by Low IGF-1 Levels. IBD Journal 2010; 138(5, Supp1).
- 69. **Crandall W**, Kappelman M, Colletti RB, Denson L, Duffy L, Grunow J, Kim S, Leibowitz I, Patel A, Schoen B, Tomer G, Milov D, Cohen S, Margolis P, and the ImproveCareNow Collaborative (formerly PIBDNet), Burlington, VT, USA. Improved Outcomes in a Quality Improvement Collaborative for Pediatric Crohn Disease. Gastroenterol 2010; 138 (5, Suppl) S29.
- 70. Walters T, Griffiths A, Hyams J, Blank M, Johanns J, Crandall W, Kugathasan S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Long-term Efficacy and Safety of Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease. The Canadian Journal of Gastroenterology February 2010; (24), Supplement SA.
- 71. Mackner L, Pajer K, Glaser R, **Crandall W**. Relationships Between Depression, Cytokines, and Cortisol in Pediatric Inflammatory Bowel Disease Gastroenterology 2010; 138 (5, Suppl 1) S303.
- 72. **Crandall W**, Kappelman M, Colletti R, Denson L, Duffy L, Grunow J, Kim S, Leibowitz I, Patel A, Schoen B, Tomer G, Milov D, Cohen S, Margolis P. Outcomes in a Quality Improvement Collaborative for Pediatric Ulcerative Colitis. Gastroenterology 2010; 138 (5, Suppl 1) S29.
- 73. Turner D, Mack D, Wine E, Hyams J, Otley A, Markowitz J, Crandall W, Mamula P, LeLeiko N, Griffiths A. A prospective multicenter study: outcomes and predictors of response to infliximab given as a rescue therapy in severe pediatric ulcerative colitis. Gastroenterology 2010; 138 (5), Suppl 1: S- (Abst 149).
- 74. Mack D, Markowitz J, Lerer T, Griffiths A, Evans J, Otley A, Bousvaros A, Pfefferkorn M, Rosh J, **Crandall W**, Michail S, Oliva-Hemker M, Kay M, Samson C, Keljo D, Kappelman M, Stephens M, Grossman A, Saeed S, LeLeiko N, Hyams J. Upper Gastrointestinal Involvement in Pediatric Crohn's Disease: Experience of a Large Multicenter Inception Cohort. Gastroenterology 2010; 138 (5, Suppl 1) S200.

- 75. Rosh J, Mohamed A, Dougherty K, Lerer T, Keljo D, Mack D, Griffiths A, Crandall W, Bousvaros A, Kay M, Grossman A, Pfefferkorn M, Michail S, Stephens M, Samson C, LeLeiko N, Oliva-Hempker M, Saeed S, Kappelman M, Otley A, Evans J, Sudel B, Markowitz J, Hyams J. Clinical Effect and Changing Patterns of Use of Methotrexate in the Treatment of Pediatric Crohn's Disease: A Multi-Center Experience. Gastroenterology 2010; 138 (5, Suppl 1) S299.
- 76. Hyams J, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J, Otley A, Evans J, Stephens M, Kay M, Keljo D, LeLeiko N, Saeed S, **Crandall W**, Michail S, Kappelman M, Sampson C, Sudel B, Oliva-Hempker M, Pfefferkorn M, Markowitz J. Outcome Following Thiopurine Use In Children With Ulcerative Colitis: A Prospective Multicenter Study. Gastroenterology 2010; 138 (5, Suppl 1) S73.
- 77. Pfefferkorn M, Langton C, Mack D, Otley A, LeLeiko N, Stephens M, Rosh J, Oliva-Hemker M, **Crandall W**, Evans J, Samson C, Kappelman M, Michail S, Hyams J, Markowitz J. NOD2 Mutations and Presenting Clinical Characteristics of Crohn's Disease (CD) in Children. Gastroenterology 2010; 138 (5, Suppl 1) S303.
- 78. Long M, Crandall W, Leibowitz I, Duffy L, Rosario F, Kim S, Integlia M, Berman J, Grunow J, Grunow J, Colletti R, Schoen B, Patel A, Baron H, Israel E, Russell G, Ali S, Herfarth H, Martin C, Kappelman M. The Prevalence and Epidemiology of Overweight and Obesity in Children with Inflammatory Bowel Disease. Am Journ Gastroenterol 2010; (Accepted)
- 79. Turner D, Mack D, Wine E, Hyams JS, Otley AR, Markowitz J, **Crandall W**, Mamula P, Leleiko N, Griffiths AM. Infliximab in steroid-refractory pediatric UC: predictors of response in a prospective multicenter study. Journ Crohns Colitis 2010; 4 (1):S63 (Abst P125)
- 80. Dotson J, Mousa H, Cunningham D, Honegger J, Jaggi P, Crandall W, Denson L, Balint J, Dienhart M, Carvalho R. Presentation and Outcomes of Histoplamosis in Pediatric IBD Patients Treated with Anti-Tumor Necrosis Factor Alpha Therapy. Inflamm Bowel Dis 2010. (Epub Ahead of print)
- 81. Peterson E, Runge T, Tolleson-Rinehart S, **Crandall W**, Colletti R, Kappelman M. Analyzing the Sustainability of a Pediatric IBD Quality Improvement Collaborative. Inflamm Bowel Dis 2011; S17(1):S37 (P-085)
- 82. Runge T, Peterson E, Tolleson-Rinehart S, Crandall W, Colletti R, Kappelman M. Perceptions of Participating in a Pediatric IBD Quality Improvement Network. Inflamm Bowel Dis 2011; S17(1):S59 (P-156)
- 83. Lee G, Kappelman M, Boyle B, Colletti R, King E, Pratt J, **Crandall W**. Are there gender differences in the clinical outcomes of pediatric inflammatory bowel disease?

- Gastroenterology May 2011 (Vol. 140, Issue 5, Supplement 1, Pages S-196-S-197, DOI: 10.1016/S0016-5085(11)60793-2)
- 84. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter H, Kugathasan S, Cohen S, Markowitz J, Veereman G, **Crandall W**, Baldassano R, Griffiths A. A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis. Gastroenterology May 2011 (Vol. 140, Issue 5, Suppl 1, Pages S-124-S-125, DOI: 10.1016/S0016-5085(11)60505-2)
- 85. Perez M, Coley B, Crandall W, DiLorenzo C, Bravender T. Effects of Nutritional Rehabilitation on Gastric Emptying, Somatic Complaints, Anxiety Disorders, and Functional Gastrointestinal Disorders in Pediatric Patients With Anorexia Nervosa. Gastroenterology May 2011 (Vol. 53, Issue 5, Suppl 1, Page E64, DOI: 10.1016/S0016-5085(11)63094-1)
- 86. Boyle B, Donegan A, **Crandall W**. IBD: Improving Outcomes through Planned Care. Pediatric Directions; 2011 (37) Q1/Q2.
- 87. Ruff J, Ross C, Mackner L, Vannatta K, **Crandall W.** Socially Interactive Technology Usage in Pediatric in Pediatric Inflammatory Bowel Disease.

 J Pediatr Gastroenterol Nutr 2011; (Vol 3, Suppl 1, Page E9)
- 88. Kumar, S., Gariepy, C. E., & **Crandall, W.** (2012). Mo1958 Nutritional Management of Pediatric Acute Pancreatitis. *Gastroenterology*, *142*(5), S-707.
- 89. Hyams, J. S., Kim, M. O., Denson, L., Stephens, M. C., Markowitz, J., Griffiths, A. M., ... Crandall W... & Walters, T. D. (2012). 138 Effect of Deep Ulceration at Diagnostic Colonoscopy on Initial Therapy and One Year Outcome in Children With Crohn's Disease. *Gastroenterology*, 142(5), S-36.
- 90. Burkam, J., Crandall, W., Bistrick, S., King, E., Pratt, J., Kappelman, M., & Colletti, R. B. (2012). 1148 Is There Seasonal Variation of Disease Activity in Pediatric-Onset Inflammatory Bowel Disease?. *Gastroenterology*, 142(5), S-209.
- 91. Walters, T. D., Dubinsky, M., Griffiths, A. M., Baldassano, R., Hyams, J. S., Stephens, M. C., ... **Crandall W**... & Kugathasan, S. (2012). 140 Anti-Microbial Serology Patterns in 824 Children With Newly Diagnosed Crohn's Disease: Association With GM-CSF Auto-Antibodies and Specific Clinical Phenotypes. *Gastroenterology*, 142(5), S-36.
- 92. Dotson, J. L., Nwomeh, B., Andridge, R. R., Anderson, S. E., & **Crandall, W.** (2012). Sa1973 Variation in Management of Intra-Abdominal Abscesses in Children With Crohn's Disease. *Gastroenterology*, 142(5), S-371.
- 93. Kumar, S., Crandall, W., & Gariepy, C. E. (2013). 122 A Prospective Study of Patient-Directed Early Nutrition in Mild Acute Pancreatitis in Children. *Gastroenterology*, 144(5), S-29.

- 94. Hyams, J. S., **Crandall, W.**, Rosh, J. R., Ruemmele, F., Escher, J. C., Lazar, A., ... & Thakkar, R. (2013). Tu1944 Efficacy and Safety of Standard vs Low Dose Adalimumab Maintenance Therapy As a Function of Disease Severity in Pediatric Patients With Crohn's Disease: Subanalysis of Imagine 1. *Gastroenterology*, 144(5), S-887.
- 95. Kugathasan, S., Dubinsky, M., Guthery, S. L., Okou, D. T., Bose, P., Zwick, M. E., ... Crandall W... & Denson, L. (2013). 976 Early Onset Crohn's Disease Exhibit Distinct Allele Architecture Differences and Reveal New IBD Loci. *Gastroenterology*, 144(5), S-178.
- 96. Hyams, J. S., Kim, M. O., Denson, L., Griffiths, A. M., Dubinsky, M., Markowitz, J., ... **Crandall W**... & Walters, T. D. (2013). 829 Early Anti-TNFα Therapy Is Superior to Early Immunomodulator Therapy in Newly Diagnosed Children With Crohn's Disease. *Gastroenterology*, 144(5), S-146.
- 97. Haberman, Y., Jurrickova, I., Dexheimer, P. J., Karrns, R., Tang, D., Bonkowski, E. L., ... Crandall W ... & Denson, L. (2013). Mo1975 Ileal RNA-Seq Analyses Reveal Decreased Mucosal Myeloid Cell Immune Responses in Pediatric Crohn Disease Patients With Phagocyte Dysfunction Due to Neutralizing Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Auto-Antibodies. *Gastroenterology*, 144(5), S-708.
- 98. Kappelman, M., Bailey, C., **Crandall, W.**, Zhang, P., King, E., Joffe, M. M., ... & Forrest, C. B. (2013). 830 Real-World Clinical and Comparative Effectiveness of Infliximab in Pediatric Crohn's Disease. *Gastroenterology*, 144(5), S-146.
- 99. Escher, J. C., Veereman-Wauters, G., **Crandall, W.**, Ruemmele, F. M., Lazar, A., Yang, M., ... & Hyams, J. (2013). P311 Adalimumab treatment is associated with improved quality of life in pediatric Crohn's disease. *Journal of Crohn's and Colitis*, 7, S133-S134.
- 100. Veereman, G., Escher, J. C., Ruemmele, F., **Crandall, W.**, Lazar, A., Skup, M., ... & Hyams, J. S. (2013). Tu1945 Adalimumab Treatment Is Associated With Improved Quality of Life in Pediatric Crohn's Disease. *Gastroenterology*, *144*(5), S-887.
- 101. Ruemmele, F. M., **Crandall, W**., Escher, J. C., Veereman-Wauters, G., Lazar, A., Skup, M., ... & Hyams, J. (2013). P223 Improved work productivity in caregivers of pediatric patients with Crohn's disease treated with adalimumab. *Journal of Crohn's and Colitis*, 7, S99.
- 102. **Crandall, W.,** Ruemmele, F., Veereman, G., Escher, J. C., Lazar, A., Yang, M., ... & Hyams, J. S. (2013). Tu1938 Improved Work Productivity in Caregivers of Pediatric Patients With Crohn's Disease Treated With Adalimumab. *Gastroenterology*, 144(5), S-885.

- 103. Dotson, J., **Crandall, W.**, Zhang, P., Forrest, C., Bailey, L. C., Colletti, R., & Kappelman, M. (2013). O-005 Feasibility and Validity of the Pediatric Ulcerative Colitis Activity Index in Real-world Clinical Practice. Inflammatory Bowel Diseases, 19, S3.
- 104. Hyams, J., **Crandall, W.**, Rosh, J., Ruemmele, F., Escher, J., Lazar, A., & Thakkar, R. (2013). O-006 Efficacy and Safety of Standard Versus Low Dose Adalimumab Maintenance Therapy as Influenced by Disease Severity in Pediatric Crohn's Disease. *Inflammatory Bowel Diseases*, 19, S3-S5.
- 105. Dotson, J., Kappelman, M., Chisolm, D., & Crandall, W. (2013). O-009 Healthcare Disparities in Hospitalized Children and Adolescents with Crohn's Disease: Is Race Associated with the Need for Readmissions?. *Inflammatory Bowel Diseases*, 19, S6-S7.
- 106. Pusateri, A., **Crandall, W.,** Dotson, J., Balint, J., Potter, C., & Kim, S. (2013). P-172 Characterizing Frequency, Pattern and Etiology of Elevated Liver Enzymes in Pediatric Inflammatory Bowel Disease Patients: A 3-Year Retrospective, Single-Center Review. *Inflammatory Bowel Diseases*, 19, S95.
- 107. **Crandall, W**; Davis, T. Nationwide Children's Cure Me Pillar: Transforming Outcome for Children. *Everything Matters: In Patient Care*, Volume 27, Issue 2, Spring 2014
- 108. Griffiths, A., **Crandall, W.**, Colletti, R., Ruemmele, F., Faubion, W. A., Hyams, J., ... & Thakkar, R. B. (2014). OP021 Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn's disease in the IMAgINE 1 trial. *Journal of Crohn's and Colitis*, 8, S12.
- 109. Gevers, D., Kugathasan, S., Denson, L., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., ... **Crandall W**., ... & Xavier, R. J. (2014). 850a The treatment-naive microbiome in early-onset Crohn's Disease. *Gastroenterology*, 146(5), S-144.
- 110. Hofmekler, T., Sauer, C., Gillespie, S., McCracken, C., Bertha, M., Walters, T. D., Crandall, W., ... & Kugathasan, S. (2014). Tu1190 Clinical Outcome and Prediction of Final Diagnosis in Pediatric Inflammatory Bowel Disease Unclassified (IBD-U) Patients. *Gastroenterology*, 146(5), S-779.
- 111. Griffiths, A. M., **Crandall, W**., Colletti, R. B., Ruemmele, F., Faubion, W. A., Hyams, J. S., ... & Thakkar, R. (2014). Sal151 Steroid-Free Remission in Adalimumab-Treated Pediatric Patients With Moderately to Severely Active Crohn's Disease in the IMAgINE 1 Trial. *Gastroenterology*, 146(5), S-213.
- 112. Dotson, J. L., Kappelman, M., Chisolm, D., & Crandall, W. (2014). 893 Healthcare Disparities in Hospitalized Children and Adolescents With Crohn's Disease: Is Race Associated With Differences in Complications or Procedures?. *Gastroenterology*, 146(5), S-157.

- 113. Haberman, Y., Tickle, T. L., Dexheimer, P. J., Huttenhower, C., Karns, R., Baldassano, R., **Crandall W.**, ... & Denson, L. (2014). 78 Host Ileal APOA1 and DUOX2 Co-Expression Modules Are Associated With Microbial Shifts and Clinical Outcomes in Treatment Naive Pediatric Crohn Disease. *Gastroenterology*, 146(5), S-22.
- 114. Boyle, B., Donegan, A. M., Kim, S. C., Dotson, J. L., & Crandall, W. (2015). Sa1060 Delivering More Comprehensive Pediatric Inflammatory Bowel Disease Care Through the Development of an Annual IBD Clinic. *Gastroenterology*, 148(4), S-210.
- Dotson, J. L., Cho, M., Bricker, J., Kappelman, M., Chisolm, D., Tomer, G., & Crandall, W. (2015). 320 Racial Differences in Initial Presentation and Early Treatment of Pediatric Crohn's Disease-Preliminary Results From the ImproveCareNow Network. *Gastroenterology*, 148(4), S-71.
- 116. Dotson, J. L., Bricker, J., Kappelman, M., Chisolm, D., & Crandall, W. (2015). Sa2001 Differences in Emergency Department Evaluation for Children and Adolescents With Crohn's Disease by Race and Insurance Status. *Gastroenterology*, 148(4), S-380.
- 117. Boyle, B., Donegan, A. M., Kim, S. C., Dotson, J. L., & Crandall, W. (2015). Sa1060 Delivering More Comprehensive Pediatric Inflammatory Bowel Disease Care Through the Development of an Annual IBD Clinic. *Gastroenterology*, 148(4), S-210.
- 118. Livshits, A., Fisher, D., Hadas, I., Bdolah-Abram, T., Mack, D., Hyams, J., ... **Crandall, W.** ... & Turner, D. (2016). Abdominal X-ray in pediatric acute severe colitis and radiographic predictors of response to intravenous steroids. *Journal of pediatric gastroenterology and nutrition*, 62(2), 259-263.
- 119. Shaikhkhalil, A., Boyle, B., Smith, J., Dotson, J., Donegan, A., Kim, S., & **Crandall, W**. (2016). P-218 Using Quality Improvement to Increase Utilization of Enteral Therapy in Pediatric Crohn Disease: Results and Clinical Outcomes. *Inflammatory Bowel Diseases*, 22, S75.
- 120. Donegan, A., Boyle, B., **Crandall, W.,** Dotson, J. L., Lemont, C., Moon, T., & Kim, S. C. (2016). Connecting Families: A Pediatric IBD Center's Development and Implementation of a Volunteer Parent Mentor Program. *Inflammatory bowel diseases*, 22(5), 1151-1156.
- 121. Drobnic, B., Kim, S., Donegan, A., Dotson, J., Boyle, B., & **Crandall, W.** (2016). P-229 YI Utilization of an Education Handbook to Optimize Self-Management Skills in Pediatric IBD: A Multidisciplinary Approach. *Inflammatory Bowel Diseases*, 22, S78.
- 122. Serpico, M., Maltz, R., **Crandall, W. V.,** Kim, S. C., Dotson, J. L., & Boyle, B. (2016). Mo1772 Combination Therapy with Thiopurines and Allopurinol Effectively Limits Hepatotoxicity and Increases Metabolite Levels in Pediatric Inflammatory Bowel Disease. *Gastroenterology*, 150(4), S772.

- 123. Kerur, B., Machan, J. T., Cerezo, C., Markowitz, J., Mack, D. R., Griffiths, A. M., ... Crandall, W. V., ... Leleiko, N.S. (2016). 21 Surgery in Pediatric Crohn's Disease, 2002-2014. *Gastroenterology*, 150(4), S7.
- 124. Kugathasan, S., Denson, L. A., Walters, T. D., Kim, M. O., Marigorta, U., Schirmer, M., ... & Crandall, W. V. (2017). 246-Early Anti-TNF is Effective in Preventing Internal Penetrating but not Stricturing Disease Complications in Children Newly Diagnosed with Crohn's Disease: A Prospective Risk Prediction Model for Disease Behavior Study. *Gastroenterology*, 152(5), S64.
- 125. Denson, L. A., Jurickova, I., Shaw, K., Linn, A., Dodd, A., Okou, D., ... Crandall, W.... (2017). Low Neutrophil Reactive Oxygen Species Production is Associated with Nicotinamide-Adenine Dinucleotide Phosphate (NADPH) Oxidase Gene Mutations and Refractory Colonic Involvement in Pediatric Crohn Disease. *Gastroenterology*, 152(5), S955.
- 126. Haberman, Y., Ben-Shoshan, M., Di-Segni, A., Dexheimer, P., Klein, T., Weiss, B., ... Crandall, W.... Denson, L.(2017). O-009 Long ncRNA Landscape in the Ileum of Treatment Naive Early Onset Crohn Disease. *Inflammatory bowel diseases*, 23, S3-S4.
- 127. Denson, L. A., Jurickova, I., Karns, R., Shaw, K. A., Cutler, D. J., Okou, D., ... & Linn, A. (2018). 27 CLINICAL AND GENOMIC CORRELATES OF NEUTROPHIL GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR SIGNALING IN PEDIATRIC CROHN DISEASE. *Inflammatory Bowel Diseases*, 24(suppl_1), S7-S8.

UNPUBLISHED SCHOLARLY WORKS

- 1. Crandall et. al. Validation of Calprotectin as a Non-Invasive Marker of Post-Operative Disease Recurrence in Patients with Crohn's' Disease. Proposal of the Crohn's and Colitis Foundation (CCFA) Clinical Trials Taskforce, 2005.
- 2. Editor, Living Well with IBD: A Self-Management Handbook (made available at no cost to patients and physicians worldwide)
- 3. Living Well with IBD: A Self-Management Program, 2013 (Web-based version of the Handbook, winner of the Apex Award of Excellence 2013-Best Use of Electronic Media for Public Service; made available at no cost to patients and physicians worldwide)

PROFESSIONAL PRESENTATIONS

1. Referral Patterns of Rural Health Care Providers. Family Practice Grand Rounds, University of Utah. 1991.

- 2. Site Directed Mutagenesis of Colipase Reveals Specific Residues that Control the Digestion of Dietary Fat by Pancreatic Triglyceride Lipase. Mead-Johnson/NASPGN Pediatric Gastroenterologists Research Forum, Scottsdale Arizona. April 2000.
- 3. Site Directed Mutagenesis of Colipase Reveals Specific Residues that Control the Digestion of Dietary Fat by Pancreatic Triglyceride Lipase. Oral Presentation, Growth, Nutrition and Development Plenary Session. Digestive Disease Week/101st Annual Meeting of the American Gastroenterological Association, San Diego California. May 2000.
- 4. Emerging Therapy for IBD: Bugs, Drugs, and Hormones. Crohn's and Colitis Foundation education lecture. Columbus Ohio. April 2001.
- 5. Inflammatory Bowel Disease- Current Care and Future Directions. Lounge and Learn. Nationwide Children's Hospital, Columbus Ohio. October 2001.
- 6. Celiac Disease: Back to the Basics. 14th Annual Celiac Conference. Columbus Ohio. November 2001.
- 7. Emerging Therapy for IBD: Bugs, Drugs, and Hormones. Crohn's and Colitis Foundation 3rd Annual Nurse's Education Program. Columbus Marriot North, Columbus Ohio. April 2002.
- 8. The Facts and Fiction of pH Probes. Pediatric Pearls. Nationwide Children's Hospital, Columbus Ohio. September 2002.
- 9. Tests for Celiac Disease. 15th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2002.
- 10. Ask the Doctor. 15th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2002.
- 11. Pediatric Gastroesophageal Reflux Disease. Medical Grand Rounds. Nationwide Children's Hospital, Columbus Ohio. January 2003.
- 12. Pediatric Gastroesophageal Reflux Disease. Outreach lecture. Marietta Memorial Hospital, Marietta Ohio. January 2003.
- 13. Treating Pediatric Patients with GERD in Clinical Practice. Dinner Meeting for Community Providers. Columbus Ohio. September 2003.
- 14. Infliximab in Pediatric IBD: Theory, Practice, and Current Research. Clinical Research Seminar, Nationwide Children's Hospital, Columbus Ohio. September 2003.

- 15. Infliximab: 5 Years Experience. Meet the Professor Breakfast. Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Montreal Canada. October 2003.
- 16. Chair, Practitioners Forum. Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Montreal Canada. October 2003.
- 17. Pediatric Gastroesophageal Reflux Disease. Grant Hospital Family Practice Lectures. Grant Hospital, Columbus Ohio. July 2004.
- 18. The Successful Design and Implementation of Clinical Trials in Adolescents with Chronic Disease-A Case Study. Invited Lecture. Pediatric Clinical Trials. Philadelphia Pennsylvania. September 2004.
- 19. Guiding the Way-Review of the New Celiac Guideline. 17th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2004.
- 20. Ask the Doctor. 17th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2004.
- 21. Moderator, Oral Abstract Presentation: Clinical Sciences session. Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Salt Lake City, Utah. October 2005.
- 22. Stress and Coping with Celiac Disease. 18th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2005.
- 23. Early Immunomodulator Use Improves 18 Month Outcomes in Pediatric Crohn Disease. Oral Presentation (Jaya Punati). Digestive Disease Week/107th Annual Meeting of the American Gastroenterological Association, Los Angelos, California. May 2006.
- 24. Celiac Disease. MedNet21 (The Ohio State University Continuing Education Webcast for the 21st Century). Columbus, Ohio. October 2006.
- 25. Celiac Immunology. 19th Annual Celiac Conference. Nationwide Children's Hospital, Columbus Ohio. November 2006.
- 26. Pediatric Inflammatory Bowel Disease: Evaluation and Management. Pediatric Grand Rounds, West Virginia University. Morgantown, West Virginia. January 2007.
- 27. Pediatric Inflammatory Bowel Disease: Evaluation and Management. Pediatric Grand Rounds, Columbus Children's Hospital. Nationwide Columbus, Ohio. February 2007.
- 28. Endocrine Disorders Associated with Pediatric Crohn Disease. Endocrinology Conference, 2007. Columbus, Ohio. April, 2007.

- 29. Meet the Professor, Pediatric IBD. Digestive Disease Week/108th Annual Meeting of the American Gastroenterological Association, Washington, DC. May 2007.
- 30. Scientific Update on Pediatric GERD in Children and Adolescents Ages 1-17 Years. Dinner Meeting for Community Providers. Columbus Ohio. October 2007.
- 31. Selected Topics in Inflammatory Bowel Disease. Lounge and Learn. Nationwide Children's Hospital, Columbus Ohio. February 2008.
- 32. The Bi-Directional Influences Between Psychosocial Factors and Disease Activity in Pediatric Inflammatory Bowel Disease. The Annual Research Retreat of The Research Institute at Nationwide Children's Hospital. Columbus, Ohio. March 2008.
- 33. Extra-Intestinal Manifestations of Pediatric Inflammatory Bowel Disease. Poster Presentation (Jen Dotson). Digestive Disease Week/Annual Meeting of the American Gastroenterological Association, San Diego California. May 2008.
- 34. Update on IBD Therapy. MedNet21 (The Ohio State University Continuing Education Webcast for the 21st Century). Columbus, Ohio. November 2008.
- 35. IBD: Yesterday, Today and Tomorrow. CCFA "Ask the Experts" Education Symposium. Columbus, Ohio. March 2009.
- 36. Moderator, Oral Abstract Presentations. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. June 2009.
- 37. Anti-Smooth-Muscle and Anti-Nuclear Antibodies do not Correlate with Increasing Severity of Liver Inflammation and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Poster Presentation (Kyle Kusek). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. June 2009.
- 38. Utilization and Effect of Methotrexate in the Treatment of Pediatric Crohn's Disease: A Multi-Center Experience. Poster Presentation (Joel Rosh). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. June 2009.
- 39. Human Alpha Defensin 5 mRNA Levels are Decreased in Children with Untreated, Newly Diagnosed Crohn's Disease. Oral Presentation (Kyle Kusek). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. June 2009.
- 40. A Single-Center Experience with Methotrexate after Thiopurine Therapy in Pediatric Crohn's Disease. Poster Presentation (Brendan Boyle). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. June 2009.

- 41. Etiology of Growth Failure in Pediatric Crohn Disease BOSS Lecture Series. The Research Institute at Nationwide Children's Hospital, August 2009
- 42. Quality Improvement in Pediatric IBD: Working Toward "Model" IBD Care. Visiting Professor/Invited Lecture. St. Louis Children's Hospital, Division of Pediatric Gastroenterology. St. Louis MO. September 2009.
- 43. Self Management in Pediatric IBD. Invited Lecture. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2009.
- 44. Research Update: Improved Outcomes in a Quality Improvement Collaborative for Pediatric Crohn's Disease. Invited Lecture. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2009.
- 45. Of EPIC Proportion: A Breakthrough in Data Management. Invited Lecture. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2009.
- 46. Moderator, "Spread and Implementation Approaches to QI" ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2009.
- 47. TNF Inhibtors: Update on Efficacy and Safety. Invited Lecture. Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. National Harbor, Maryland. November 2009.
- 48. Improved Outcomes in a Quality Improvement Collaborative for Pediatric Crohn Disease. Poster Presentation. Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. National Harbor, Maryland. November 2009.
- 49. Presentation and Outcomes of Histoplamosis in Pediatric IBD Patients Treated with Anti-Tumor Necrosis Factor Alpha Therapy. Poster Presentation (Jen Dotson). Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. National Harbor, Maryland. November 2009.
- 50. Poor Growth in Crohn's Disease is Caused by Low IGF-1 Levels. Poster Presentation (Dana Hardin). 2009 Advances in Inflammatory Bowel Diseases. Hollywood, Florida. December 2009.
- 51. Improved Outcomes in a Quality Improvement Collaborative for Pediatric Crohn Disease. Oral Presentation. 2009 Advances in Inflammatory Bowel Diseases. Hollywood, Florida. December 2009.
- 52. Understanding Inflammatory Bowel Disease: What Every Patient Needs to Know. Crohn's and Colitis Foundation of America Patient Education Program. Columbus State Community College. Columbus, Ohio. March 2010.

- 53. A Systems View of Model IBD Care. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2010.
- 54. Shared Baselines in Model IBD Care. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2010.
- 55. Enhanced Population Management in Pediatric IBD. Moderator (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2010.
- 56. Psychological Symptoms in Inflammatory Bowel Disease: Do Mast Cells Play a Role? Poster Presentation (Laura Mackner). 31st Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. Seattle, Washington. April 2010.
- 57. Relationships Between Depression, Cytokines, and Cortisol in Pediatric Inflammatory Bowel Disease. Poster Presentation (Laura Mackner). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, New Orleans, LA. May 2010.
- 58. Improved Outcomes in a Quality Improvement Collaborative for Pediatric Ulcerative Colitis. Oral Presentation. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, New Orleans, LA. May 2010.
- 59. Taking Your IBD Medications. Moderator, CDHNF Webcast. June 2010
- 60. Population Management: Where Are We Now and Where Are We Going? Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2010.
- 61. Implementing QI into a Pediatric IBD Practice. Invited Lecture. CCFA IBD Quality Improvement Summit. New York, NY. October 2010
- 62. NASPGHAN and CCFA QI Collaborative Opportunities. Invited Lecture. CCFA IBD Quality Improvement Summit. New York, NY. October 2010
- 63. Quality Improvement in Pediatric Inflammatory Bowel Disease Moderator: NASPGHAN Post Graduate Course. New Orleans, LA. October 2010
- 64. QI Tools for Transforming Your Practice. Invited Lecture. NASPGHAN Post Graduate Course. New Orleans, LA. October 2010
- 65. Invited Panelist. "Advances in IBD". Columbus OH, November 2010.
- 66. Development of Automated Pre-Visit Planning and Population Management Tools for Pediatric IBD. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.

- 67. Expanding our Self-Management Support Resources: Introducing the IBD Handbook. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.
- 68. Changes that Work. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.
- 69. Meet the Professor, Quality Improvement in Pediatric IBD. Invited Lecture. Digestive Disease Week, Annual Meeting of the American Gastroenterological Association, Chicago IL. May 2011.
- 70. Moderator, Pediatric Gastroenterology: Clinical and Translational Research. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago, Illinois. May 2011.
- 71. Are there gender differences in the clinical outcomes of pediatric inflammatory bowel disease? Oral Presentation (Grace "Jenny" Lee). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago IL. May 2011.
- 72. Effects of Nutritional Rehabilitation on Gastric Emptying, Somatic Complaints, Anxiety Disorders, and Functional Gastrointestinal Disorders in Pediatric Patients With Anorexia Nervosa. Poster Presentation (Maria Perez). Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago IL. May 2011.
- 73. Pre-Visit Planning and Population Management in Action. Invited Lecture. Pediatric Rheumatology (PR)-COIN Learning Session, Cincinnati OH, June 2011
- 74. Diffusion of Innovations. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.
- 75. Population Management. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.
- 76. Pre-Visit Planning. Invited Lecture (Meeting Faculty). ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2011.
- 77. Effects of Nutritional Rehabilitation on Gastric Motility and Somatization in Anorexia. Poster Presentation (Maria Perez). NASPGHAN Annual Meeting, Orlando FL. October 2011.
- 78. Socially Interactive Technology Usage in Pediatric Inflammatory Bowel Disease (IBD). Poster Presentation (Jessica Ruff). NASPGHAN Annual Meeting, Orlando FL. October 2011.
- 79. Meet the Professor, Challenging Cases in Pediatric Inflammatory Bowel Disease. Invited Lecture. NASPGHAN Annual Meeting, Orlando FL. October 2011.

- 80. Moderator, Controversies in Pediatric GI. NASPGHAN Annual Meeting, Orlando FL. October 2011.
- 81. Pre-Visit Planning and Population Management in Action. Inaugural Pediatric Rheumatology Grand Rounds, Nationwide Children's Hospital. October 2011.
- 82. Improving Quality and Outcomes in Pediatric IBD. Invited Lecture. Duke University/Children's Hospital and Health Center, Department of Pediatrics. Durham NC. December 2011.
- 83. Improving Quality and Outcomes in Pediatric IBD. Invited Lecture. Texas Children's Hospital, Division of Pediatric Gastroenterology. Houston TX. December 2011.
- 84. Risk Stratification of Pediatric IBD: What Disease Does Your Patient Really Have? Invited Lecture. Great Debates and Updates in Inflammatory Bowel Disease. New York, NY. March 2012
- 85. Nutritional Management of Pediatric Acute Pancreatitis. Poster of Distinction (Soma Kumar). Digestive Disease Week/Annual Meeting of the American Gastroenterological Association. San Diego, California. May 2012.
- 86. Is There Seasonal Variation of Disease Activity in Pediatric-Onset Inflammatory Bowel Disease? Oral Presentation (Jen Burkam). Digestive Disease Week/Annual Meeting of the American Gastroenterological Association. San Diego, California. May 2012.
- 87. Variation in Management of Intra-Abdominal Abscesses in Children with Crohn's Disease Poster Presentation (Jen Dotson). Digestive Disease Week/Annual Meeting of the American Gastroenterological Association. San Diego, California. May 2012.
- 88. Moderator: Pediatric IBD Clinical and Translational Research. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, San Diego, California. May 2012.
- 89. Moderator: FDA Sponsored Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT); Public Workshop. Baltimore MD, September 2012.
- 90. Innovation for All: Pre-Visit Planning and Population Management. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2012.
- 91. The SM Handbook: Present and Future. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2012.
- 92. Ready for the New Era: Cementing and Spreading Network Innovations. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2012.

- 93. Lead Pellet Ingestion. Poster Presentation (Patrice Kruszewski). NASPGHAN Annual Meeting, Salt Lake City UT. October 2012.
- 94. State of the Art: Pediatric IBD as the Model for Improving Chronic Care. Discovering the Future of Pediatric Inflammatory Bowel Disease Care. Single Topic Symposium at the NASPGHAN Annual Meeting, Salt Lake City UT. October 2012.
- 95. A Comprehensive Family Centered Quality and Safety Strategic Plan. Creating Connections; Children's Hospital Association. Orange County CA. March 2013.
- 96. Invited Lecture. The Learning Healthcare System: The Future of Pediatric IBD Care. CCFA Patient and Physician Day. Atlanta GA. March 2013.
- 97. Invited Lecture. Becoming Part of Your Healthcare Team. Patient and Physician Day. Atlanta GA. March 2013.
- 98. Strategies to Enhance Self-Management Support: Focus on Adherence. ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2013.
- 99. Pre-Visit Planning and Population Management in the New Era. ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2013.
- 100. The Basics: Population Management and Pre-Visit Planning 101. ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2013.
- 101. ImproveCareNow Strategic Initiatives: Restructuring QI Support and Curriculum. ImproveCareNow Semi-Annual Meeting. Chicago IL. April 2013.
- 102. Nutritional Management of Pediatric Acute Pancreatitis. Oral Presentation (Soma Kumar). Digestive Disease Week/Annual Meeting of the American Gastroenterological Association. Orlando, FL. May 2013.
- 103. Invited Lecture. Decision Making in Ulcerative Colitis: Escalate Medical Therapy or Call the Surgeon? Postgraduate Course; NASPGHAN Annual Meeting. Chicago IL. October 2013.
- 104. Meet the Professor Lunch. Challenging Cases in Ulcerative Colitis. Postgraduate Course; NASPGHAN Annual Meeting. Chicago IL. October 2013.
- 105. Enhancing QI Culture. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2013.
- 106. Clinical Pathways: Our Road to Best Outcomes? ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2013.

- 107. The Draft ICN Curriculum: Building your QI Toolbox. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2013.
- 108. The Automation Era: Lessons Learned to Date. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2013.
- 109. IHI Symposium: Building the ImproveCareNow Learning Health System. A Week in the Life: ImproveCareNow in Action. IHI National Forum. Orlando Fl. December 2013.
- 110. Invited Lecture. ImproveCareNow and the Learning Healthcare System. CIDsCaNN QI Symposim. Toronto Canada. February 2014.
- 111. ImproveCareNow Interventions and Model Care Guidelines. ImproveCareNow Semi-Annual Meeting. Chicago IL. May 2014.
- 112. ImproveCareNow Innovation Updates. ImproveCareNow Semi-Annual Meeting. Chicago IL. May 2014
- 113. Clinical Pathways in ImproveCareNow. ImproveCareNow Semi-Annual Meeting. Chicago IL. May 2014
- 114. Moderator: Controversies in Pediatric IBD. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago IL. May 2014.
- 115. Steroid-free remission in adalimumab-treated pediatric patients with moderately to severely active Crohn's disease in the IMAgINE 1 trial. Poster Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, Chicago IL. May 2014
- 116. ImproveCareNow Interventions and Model Care Guidelines. ImproveCareNow Semi-Annual Meeting. Chicago IL. October 2014.
- 117. Nutritional Therapy for Pediatric IBD: It's Not Them, It's Us. Frontiers in Pediatric Gastroenterology, Hepatology and Nutrition. Boston MA. September 2014.
- 118. Quality Outcomes in Intestinal Failure: Lessons from a Learning Health System. Keynote Speaker, 8th International Pediatric Intestinal Failure and Rehabilitation Symposium. Atlanta GA. September 2014.
- 119. Meet the Professor Breakfast. Medical Management of Ulcerative Colitis. NASPGHAN Annual Meeting. Atlanta, GA. October 2014.
- 120. Medical Inflammatory Bowel Disease. 2014 Pediatric Colorectal, Motility and Pelvic Reconstruction Conference. Columbus Ohio. November 2014.

- 121. Panelist, Surgical Inflammatory Bowel Disease. 2014 Pediatric Colorectal, Motility and Pelvic Reconstruction Conference. Columbus Ohio. November 2014.
- 122. Cure Me: A Systematic Approach to Improving Patient Outcomes. Oral Presentation. Children's Hospital Association Quality and Safety in Children's Health Conference. San Francisco, California. March 2015.
- 123. Building Toward New Interventions. ImproveCareNow Semi-Annual Meeting. Chicago IL. March 2015.
- 124. ICN Interventions and Model Care Guidelines. ImproveCareNow Semi-Annual Meeting. Chicago IL. March 2015.
- 125. Markers of Remission. ImproveCareNow Semi-Annual Meeting. Chicago IL. March 2015.
- 126. ICN Interventions and Model Care Guidelines. ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2015.
- 127. Improving our Improvement Tools: Strengthening our QI Foundation. ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2015.
- 128. Evaluation of PROMIS Measures for Pediatric Inflammatory Bowel Disease. ImproveCareNow Semi-Annual Meeting. Chicago IL. September 2015.
- 129. Increasing the Use of Enteral Therapy in Pediatric Crohn Disease Using a Systematic Quality Improvement Approach: Results and Clinical Outcomes. Poster Presentation (Ala Shaikhkhalil). NASPGHAN Annual Meeting. Washington DC. October 2015.
- 130. Invited Lecture. ImproveCareNow: Expanding on a Decade of Learning. NASPGHAN Annual Meeting. Washington DC. October 2015.
- 131. Panelist- Key Learning and Challenges. Learning Networks CHILD Workshop. Erlanger, KY. October 2015.
- 132. Cure Me: Using QI Science to Systematically Transform Clinical Outcomes. Poster Presentation. Academy For Healthcare Improvement's Teaching and Disseminating Methods to Improve Healthcare Quality and Affordability. Alexandria, VA. October 2015.
- 133. Relationship Between Quality Improvement Competencies and Individual/Institutional Productivity After Formalized Experiential Training in QI Methodology. Oral Presentation. Academy For Healthcare Improvement's Teaching and Disseminating Methods to Improve Healthcare Quality and Affordability. Alexandria, VA. October 2015.

- 134. Moderator: IBD Clinical Case Reviews. Pediatric Colorectal, Motility and Pelvic Reconstruction Conference. Columbus, OH. November 2015.
- 135. Moderator: Inflammatory Bowel Disease. Pediatric Colorectal, Motility and Pelvic Reconstruction Conference. Columbus, OH. November 2015.
- 136. Invited Lecture. Quality Improvement Overview: Aim and Key Driver Diagrams. Ohio Better Birth Outcomes (OBBO) meeting. Columbus, OH. November 2015.
- 137. Cure Me: Using QI Science to Systematically Transform Clinical Outcomes. Poster Presentation. Institute for Healthcare Improvement Scientific Symposium. Orlando, FL. December 2015.
- 138. Connecting Families: Development and Implementation of a Parent Mentoring Program. Oral Presentation. Children's Hospital Association Quality and Safety in Children's Health Conference. New Orleans, LA. March 2016.
- 139. The Systematic Use of Clinical Indices to Improve Care. Oral Presentation. Children's Hospital Association Quality and Safety in Children's Health Conference. New Orleans, LA. March 2016.
- 140. ImproveCareNow as Your Learning Healthcare System. ImproveCareNow Semi-Annual Meeting. Dallas, TX. April 2015.
- 141. Innovate, Test, Spread: Our Evolving QI and Innovation Structure. ImproveCareNow Semi-Annual Meeting. Dallas, TX. April 2015.
- 142. Measuring and Improving Quality of Care in Pediatric IBD. Invited Oral Presentation. Digestive Disease Week/ Annual Meeting of the American Gastroenterological Association, San Diego, CA. May 2016.
- 143. ImproveCareNow as Your Learning Healthcare System. ImproveCareNow Semi-Annual Meeting. Chicago, IL. September, 2016.
- 144. Preoccupation with Success: Learning from Safety II Concepts. ImproveCareNow Semi-Annual Meeting. Chicago, IL. September, 2016.
- 145. Meet the Professor. Management of Intra-Abdominal Abscess and Phelgmon in Crohn's Disease. World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Montreal, Quebec. October 2016.
- 146. (Invited Keynote) Biosimilars: What Patients Should Know. CCFA Central Ohio IBD Education Day. Columbus, OH. October, 2016.
- 147. Expert Q & A Panel: Transition from Pediatric to Adult IBD Care. CCFA Central Ohio IBD Education Day. Columbus, OH. October, 2016.

- 148. Moderator: Inflammatory Bowel Disease. Pediatric Colorectal, Motility and Pelvic Reconstruction Conference. Columbus, OH. November 2016.
- 149. Caring for a Population: Lessons from the World of QI. Nationwide Children's Hospital Pediatric GI Symposium. Columbus, OH. June 2017.
- 150. ImproveCareNow as Your Learning Healthcare System. ImproveCareNow Semi-Annual Meeting. Chicago, IL. September 2017.
- 151. Moderator: Tipping Point Leadership. ImproveCareNow Semi-Annual Meeting. Chicago, IL. September 2017.
- 152. Moderator: Finding Your Place on Your QI Team. ImproveCareNow Semi-Annual Meeting. Chicago, IL. September 2017.
- 153. Visiting Professor/Grand Rounds. Improving Improvement and Why You Should Care. New York, NY. February 2018
- 154. A Clinician Perspective on Being Part of a Learning Health System. PCORNet Learning Health Systems Meeting. Cincinnati, OH. February 2018.
- 155. Developing an Effective Quality Improvement Training Program. Children's Hospital Association Quality and Safety Leaders Forum. San Diego, CA. March 2018.
- 156. The Importance of ImproveCareNow in Achieving Optimal Health and Care. ImproveCareNow Semi-Annual Meeting. Dallas, TX. April 2018.
- 157. Blowing Up Your QI Program. ImproveCareNow Semi-Annual Meeting. Dallas, Tx. April 2018.
- 158. Course Co-Director. The Young Adult IBD Conference on Transition of Care. Columbus, OH. May 2018.
- 159. Panelist, Adolescents in Adult Clinical Trials: Implementing the Vision. Oct. 15-16; Pooks Hill Marriott Bethesda, Md. (2019)
- 160. Moderator, Adolescents in Adult Clinical Trials: Implementing the Vision. Oct. 15-16; Pooks Hill Marriott Bethesda, Md. (2019)
- 161. Invited Speaker, Development of Immunomodulators, Developing Treatments for COVID-19; I-ACT Virtual Workshop (2020)
- 162. Invited Speaker, Pediatric Development in IBD- An Industry Perspective. April 14-15; c4c IBD Multistakeholder Meeting Virtual Conference (2021)

- 163. Invited Speaker, Why QI- An Industry Introduction. May 24; PICTR Trailblazer Learning Session 1; Virtual Conference (2021)
- 164. Invited Speaker, Advances in Clinical Trials, Challenges and Solutions- An Industry Perspective. September 7-10. 6th International Symposium on Pediatric Inflammatory Bowel Disease (2022).

PRIOR RESEARCH FUNDING

- 1. A Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects with Moderate to Severe Crohn's Disease. Site PI. December 2002-2006. Total \$230,000 (Direct \$230,000)
- 2. A Multicenter International Observational Study of the Long-Term Safety of Infliximab. Site PI. March 2003-2009. Total \$8,300 (Direct \$6,906)
- 3. A phase 3, Randomized, Open-Label, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (Remicade) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis. Site PI. July 2006-2009. Total \$65,873 (Direct \$65,873)
- 4. A Multicenter, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti TNF Monoclonal Antibody Adlimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease. Site PI. March 2007-present. Total \$150,620 (Direct \$111,571)
- 5. A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study. Site PI. September 2008-August 2011. Total \$45,192 (Direct \$37,660)
- 6. Pediatric IBD Registry (Hyams, University of Connecticut Medical Center). Site PI. January 2008-2010. Total \$4,000 (Direct \$3,636)
- 7. Predicting Response to Intravenous Corticosteroids Therapy in Pediatric Patients with Ulcerative Colitis (Turner). Site PI. November 08-October 10. Total \$6,000 (Direct \$5,455)
- 8. Retrospective Evaluation of the Safety and Efficacy of Adalimumab in the Treatment of Inflammatory Bowel Disease in Children Protocol (RESEAT). Site PI. October 2007-October 2009. Total \$3,000 (Direct \$2,400)

- 9. Copper Status in Cholestatic Neonates and Infants Receiving Reduced Doses of Copper Supplementation in Their Parenteral Nutrition (Deinhart, The Research Institute at Nationwide Children's Hospital). Co-Investigator. July 2008-June 2010. Total \$5,300 (Direct \$5,300)
- 10. Depression, Cytokines and Cortisol in Pediatric IBD (Mackner, Broad Foundation). Co-Investigator. June 08- May-09. Total \$323,916 (Direct \$295,444), Comp: 2%
- 11. Inflammation and Depression in Pediatric IBD (Mackner, Wolfe Foundation). Co-Investigator. December 07-December 09. Total \$88,000 (Direct \$88,000), Comp: 0%
- 12. Effects of nutritional rehabilitation on gastric emptying and somatic complaints in pediatric anorexia patients (Perez, The Research Institute at Nationwide Children's Hospital). Co-Investigator. October 2009-September 2011. Total \$9,930 (Direct \$9,930), Comp: 0%
- 13. Building Modular Pediatric Chronic Disease Registries for QI and CE Research (Hutton, NIH, 1 R01 HS020024-01). Co-Investigator. September 2010- September 2013. Total \$11,994,560 (Direct 7,824,119) Comp: 15%
- 14. Social Functioning in Adolescent Chronic Illness (Mackner, 1R01HD058317-01A2) Co-Investigator May 2008-May 2013. Total \$1,679,563.00 (Direct \$1,167,509) Comp: 15.5%
- 15. Bridging the gap between stress and clinical outcomes: the stress response system in pediatric Crohns disease (Mackner/Crandall, The Research Institute at Nationwide Children's Hospital) Co-PI. January 2011-December 2012. Total \$25,000 (Direct \$25,000): Comp 0% (10% institutional release time)
- 16. Early Enteral Nutrition in Mild Acute Pediatric Pancreatitis (Kumar, The Research Institute at Nationwide Children's Hospital). Co-Investigator. November 1, 2010-October 31, 2012. Total \$3,298 (Direct \$3,298): Comp 0%
- 17. Conference: "Discovering the Future of Pediatric IBD Care" (Crandall, CCFA Ref. # 3777). PI. October 2012. Total \$10,000 (Direct \$10,000): Comp 0%
- 18. Conference: "Discovering the Future of Pediatric IBD Care" (Crandall, 1 R13 DK096897-01). PI. October 2012. Total \$20,000 (Direct \$20,000): Comp 0%
- 19. Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (Kugathasan, The Crohn's and Colitis Foundation of America). Site PI. July 2009-June 2014. Total \$109,579 (Direct \$99,617) Comp: 0%
- 20. Building Modular Pediatric Chronic Disease Registries for QI and CE Research

- (ImproveCareNow Subcontract). Site PI. May 2011- May 2014. Total \$75,000 (Direct \$75,000)
- 21. ImproveCareNow: A Learning Health System for Children with Crohn's Disease & Ulcerative Colitis (Margolis, Patient Centered Outcomes Research Institute). Co-I. Jan 2014-June 2015. \$49,351. Comp 10%.
- 22. Telehealth Enhancement of Adherence to Medication (TEAM) in Pediatric IBD (Hommel, NIH, R01HD067174-01). Co-Investigator. August 2011-July 2016. Total \$2,544,016 (Direct \$1,762,170):Comp 5%
- 23. Developing a Peer Mentoring Program to Improve Self-Management in Youth with IBD (Mackner, NIH R21HD073609). Co-Investigator. April 2013-March 2016. Total \$445,709: Comp 1%
- 24. Peer Mentoring in Pediatric IBD: A Pilot Study (Mackner, Crohn's and Colitis Foundation of America). Co-Investigator. January 1, 2016-December 31, 2019. Total \$3,756,846 (Direct \$3,166,809): Comp 5%
- 25. The Effect of Provider Bias and Patient/Family Hardships on Healthcare Disparities in Pediatric Inflammatory Bowel Disease (Dotson, The Crohn's and Colitis Foundation of America). Mentor.

TEACHING

2000 - 2019	Inpatient Attending Service 4 weeks per year Variable lecture topics 3-4 days per week Nationwide Children's Hospital, Columbus Ohio
01/2001	Introduction to Inflammatory Bowel Disease Doctor's Hospital, Columbus Ohio Resident CORE lecture series
01/2001	GI Bleeding: If, Where, and Why Doctor's Hospital, Columbus Ohio Resident CORE lecture series
03/2001	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
09/2001	Introduction to Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Resident lecture series

03/2002	Inflammatory Bowel Disease Doctor's Hospital, Columbus Ohio Resident CORE lecture series
03/2002	Celiac Disease Doctor's Hospital, Columbus Ohio Resident CORE lecture series
08/2002	Medications in IBD Nationwide Children's Hospital, Columbus Ohio Nurse Practitioner lecture series
11/2002	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric Surgery Resident/Fellow Lecture Series
11/2002	GI Bleeding: If, Where, and Why Nationwide Children's Hospital, Columbus Ohio Pediatric House staff Lecture Series
01/2003	Pediatric GERD Doctor's Hospital, Columbus Ohio Resident CORE lecture series
01/2003	Facts and Fiction of pH Probes Doctor's Hospital, Columbus Ohio Resident CORE lecture series
11/2003	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
01/2004	Inflammatory Bowel Disease Doctor's Hospital, Columbus Ohio Resident CORE lecture series
01/2004	Celiac Disease Doctor's Hospital, Columbus Ohio Resident CORE lecture series
02/2004	GI Bleeding: If, Where, and Why Nationwide Children's Hospital, Columbus Ohio Pediatric House staff Lecture Series
03/2005	The Urgent GI Referral Nationwide Children's Hospital, Columbus Ohio

Pediatric Housestaff Lecture Series

09/2005	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric Housestaff Lecture Series
11/2006	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
01/2007	Inflammatory Bowel Disease The Ohio State University School of Medicine Med II Integrated Pathway lecture
09/2007	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric Housestaff Lecture Series
11/2007	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
02/2008	Diarrhea Nationwide Children's Hospital, Columbus Ohio MS3 Lecture Series
11/2008	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
03/2009	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric resident lecture series
03/2009	Working Toward Model IBD Care Nationwide Children's Hospital, Columbus Ohio Division Meeting
11/2009	Inflammatory Bowel Disease Nationwide Children's Hospital, Columbus Ohio Pediatric surgery resident/fellow lecture series
03/2010	Quality Improvement in Inflammatory Bowel Disease: The Year in Review

Nationwide Children's Hospital, Columbus Ohio

Division Meeting

06/2011 Building the Future of Pediatric IBD Care

Nationwide Children's Hospital, Columbus Ohio

Division Meeting

2012 Enhancing QI Culture within Demands of Patient Care

Nationwide Children's Hospital

Quality Improvement Essential Course

2013-2015 National Collaboratives: Opportunities and Challenges

Recurring twice yearly Nationwide Children's Hospital

Quality Improvement Essential Course

2014- Present Practical Tips to Publish and Present QI Work

Recurring twice yearly Nationwide Children's Hospital

Quality Improvement Essential Course

2013 - Present Key Driver Diagrams

Multiple times yearly Nationwide Children's Hospital, Columbus Ohio

QI Education for Residents and Fellows

2012 - Present Executive Coach for QI Essentials Course Participants (2-4/yr)

Nationwide Children's Hospital

Quality Improvement Essential Course

2014 Overview of IBD therapeutics

Nationwide Children's Hospital, Columbus Ohio

Fellow Clinical Conference

2016 - Present Getting Your QI Project Off the Ground

Recurring twice yearly Nationwide Children's Hospital

Quality Improvement Essential Course

2016 – Present Multiple Topics

Recurring twice yearly Nationwide Children's Hospital, Columbus Ohio

QI Writing Group